	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)	CLUSTER	PREPROCESSED_SENTENCE
S29-PMC1852384	PMC1852384	1/2007	S29-PMC1852384	['over time, ADDITIONAL preoperative STUDIES, including serum Insulin, iron, ferritin, Vitamin B12, 25-Oh Vitamin D, and Thiamine (Vitamin B1) were added.rygb was performed in a standard fashion with the following common elements: (1) open technique; (2) 20–30\xa0ml pouch, nondivided Stomach, ta 90b (us surgical, norwalk, ct, usa) applied twice; (3) hand-sewn two-layer retrocolic, Antegastric Gastrojejunostomy, 12\xa0mm in length, tested with Methylene Blue under pressure intraoperatively; (4) side-to-side, functional end-to-end Jejunojejunostomy with dispsable Gia (us surgical) or lc (ethicon endosurgery, sommerville, nj, usa) 75\xa0mm staplers, and ta55 (us surgical) or Tx 60 (ethicon endosurgery) staplers and routinely oversewn with 3–0 silk lembert Sutures.']	[('FUTURE_WORK', 11), ('FUTURE_WORK', 35)]	2	[('PR_000045358', 'insulin family protein', 60, 'insulin'), ('CHEBI_33279', 'vitamin D5', 85, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 85, 'vitamin B12'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 98, '25-OH'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('CHEBI_26948', 'vitamin B1', 119, 'thiamine'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 129, 'vitamin B1'), ('UBERON_0000945', 'stomach', 280, 'stomach'), ('UBERON_0008960', 'melon organ', 379, 'antegastric'), ('UBERON_0003487', 'skin sebaceous gland', 391, 'gastrojejunostomy'), ('CHEBI_6872', 'methylene blue', 439, 'methylene blue'), ('UBERON_0003655', 'molar tooth', 527, 'jejunojejunostomy'), ('UBERON_0003631', 'pedal digit 1', 560, 'GIA'), ('CHEBI_9750', 'Triton X-100', 670, 'TX'), ('UBERON_4200215', 'suture', 752, 'sutures')]	0	['time, preoperative studies, serum iron, ferritin, vitamin b12, 25-oh thiamine (vitamin b1) added.rygb fashion following elements: (1) technique; (2) 20–30\xa0ml pouch, nondivided stomach, ta 90b (us surgical, norwalk, ct, usa) twice; (3) hand-sewn two-layer retrocolic, antegastric gastrojejunostomy, 12\xa0mm length, methylene blue pressure intraoperatively; (4) side-to-side, functional end-to-end jejunojejunostomy dispsable gia (us surgical) lc (ethicon endosurgery, sommerville, nj, usa) 75\xa0mm staplers, ta55 (us surgical) tx 60 (ethicon endosurgery) staplers routinely oversewn 3–0 silk lembert sutures.']
S15-PMC2582131	PMC2582131	11/2008	S15-PMC2582131	['for instance, in both Animal and Human studies, Vitamin D depletion was significantly RELATED to Insulin resistance and impaired Insulin secretion.']	[('SUPERFICIAL_RELATIONSHIP', 86)]	1	[('NCBITaxon_33208', 'Metazoa', 22, 'animal'), ('NCBITaxon_9606', 'Homo sapiens', 33, 'human'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('PR_000045358', 'insulin family protein', 97, 'insulin'), ('PR_000045358', 'insulin family protein', 129, 'insulin')]	0	['instance, animal human studies,  depletion  resistance  secretion.']
S90-PMC2582131	PMC2582131	11/2008	S90-PMC2582131	['second, Vitamin D CAN promote Insulin sensitivity by stimulating the Expression of Insulin receptors and enhancing Insulin responsiveness for Glucose transport.']	[('INCOMPLETE_EVIDENCE', 18)]	1	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('PR_000045358', 'insulin family protein', 30, 'insulin'), ('GO_0010467', 'gene expression', 69, 'expression'), ('PR_000045358', 'insulin family protein', 83, 'insulin'), ('PR_000045358', 'insulin family protein', 115, 'insulin'), ('CHEBI_17234', 'glucose', 142, 'glucose')]	0	['second,   sensitivity expression  receptors  responsiveness glucose transport.']
S93-PMC2582131	PMC2582131	11/2008	S93-PMC2582131	['for instance, Endogenous Production Of Vitamin D In the Skin due to sun exposure is a MAJOR source of Plasma 25-[Oh] D. sun exposure could be positively CORRELATED with outdoor physical activity, a PROTECTIVE FACTOR for Insulin resistance and gdm[32]–[34].']	[('IMPORTANT_CONSIDERATION', 86), ('SUPERFICIAL_RELATIONSHIP', 153), ('SUPERFICIAL_RELATIONSHIP', 198)]	3	[('GO_0009790', 'embryo development', 14, 'endogenous'), ('GO_1902907', 'proteasome storage granule disassembly', 25, 'production of vitamin D in ... skin'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 102, 'plasma'), ('CHEBI_34300', '2-naphthoyl-CoA', 109, '25-[OH] D'), ('PR_000045358', 'insulin family protein', 220, 'insulin')]	0	['instance, endogenous production  skin sun exposure plasma 25-[oh] d. sun exposure positively outdoor physical activity,  resistance gdm[32]–[34].']
S115-PMC2582131	PMC2582131	11/2008	S115-PMC2582131	['longitudinal STUDIES with serial measurements of maternal Plasma 25-[Oh] D concentrations, indices of Insulin sensitivity and secretion ARE NEEDED to ELUCIDATE the mechanisms and patho-physiological consequences of maternal Vitamin D deficiency during Pregnancy.']	[('FUTURE_WORK', 13), ('FUTURE_WORK', 136), ('FUTURE_WORK', 150)]	3	[('UBERON_0001969', 'blood plasma', 58, 'plasma'), ('CHEBI_34300', '2-naphthoyl-CoA', 65, '25-[OH] D'), ('PR_000045358', 'insulin family protein', 102, 'insulin'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('GO_0007565', 'female pregnancy', 252, 'pregnancy')]	0	['longitudinal serial measurements maternal plasma 25-[oh] concentrations, indices  sensitivity secretion mechanisms patho-physiological maternal  pregnancy.']
S118-PMC2582131	PMC2582131	11/2008	S118-PMC2582131	['HOWEVER, DUE TO the PREDISPOSITION of asian, black, and hispanic women for Insulin resistance and Vitamin D deficiency, IT IS POSSIBLE that adequate Vitamin D status MAY BE even more IMPORTANT in these populations.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBLEM_COMPLICATION', 9), ('SUPERFICIAL_RELATIONSHIP', 20), ('INCOMPLETE_EVIDENCE', 120), ('INCOMPLETE_EVIDENCE', 166), ('IMPORTANT_CONSIDERATION', 183)]	6	[('PR_000045358', 'insulin family protein', 75, 'insulin'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D')]	0	['however, asian, black, hispanic women  resistance  deficiency,  status populations.']
S128-PMC2873552	PMC2873552	4/2010	S128-PMC2873552	"['[""""caption (table-wrap): table 2\\n\\nfunctions and diseases related to both ceu and yri Signaturesceuyri diabetes 1.70e-172.70e-20 Coronary Artery disease 3.78e-173.12e-13 Genetic disorder 1.09e-144.53e-14 Cardiovascular disease 1.34e-144.78e-11 non-Insulin-dependent diabetes mellitus 1.03e-128.66e-15 Endocrine System disorder 1.91e-121.25e-18 hypertension 2.13e-122.83e-11 Neurological disorder 2.49e-123.27e-12 crohn\'s disease 7.59e-127.25e-09 bipolar affective disease 3.50e-115.24e-09 Metabolic disorder 5.66e-119.83e-16 inflammatory disorder 2.56e-091.08e-08 Digestive System disorder 2.66e-091.31e-07 Skeletal and muscular disorder 1.49e-081.58e-08 progressive motor neuropathy 2.53e-085.59e-12 Autoimmune disease 7.28e-081.09e-12 immunological disorder 2.46e-073.66e-13 rheumatoid arthritis 3.78e-072.54e-07 shape change of Epithelial Cells 8.86e-07 alzheimer\'s disease 3.60e-062.27e-07 parkinson\'s disease 7.24e-065.29e-06 shape change of Dermal Cells 9.33e-06 Insulin-dependent diabetes mellitus 3.76e-15 neuropathy 5.38e-12 amyotrophic lateral sclerosis 1.36e-09 arthritis 1.44e-07\\n\\nVitamin D HYPOTHESIS\\nan INTERESTING HYPOTHESIS HAS BEEN PROPOSED by mcgrace [28] claiming that low Prenatal Vitamin D increases the risk of a wide range of diseases such as multiple sclerosis, diabetes, schizophrenia, Prostate cancer, Breast cancer and Colorectal cancer because of its versatile function in normal development.""""]']"	[('INCOMPLETE_EVIDENCE', 1099), ('ANOMALY_CURIOUS_FINDING', 1113), ('INCOMPLETE_EVIDENCE', 1125), ('INCOMPLETE_EVIDENCE', 1136), ('INCOMPLETE_EVIDENCE', 1145)]	5	[('GO_0036367', 'light adaption', 82, 'signaturesCEUYRI'), ('UBERON_0001621', 'coronary artery', 125, 'Coronary artery'), ('SO_0000704', 'gene', 166, 'Genetic'), ('UBERON_0004535', 'cardiovascular system', 200, 'Cardiovascular'), ('PR_000045358', 'insulin family protein', 244, 'insulin'), ('UBERON_0000949', 'endocrine system', 297, 'Endocrine system'), ('UBERON_0001016', 'nervous system', 370, 'Neurological'), ('GO_0008152', 'metabolic process', 485, 'Metabolic'), ('UBERON_0004854', 'gastrointestinal system mesentery', 560, 'Digestive system'), ('UBERON_0004288', 'skeleton', 603, 'Skeletal'), ('UBERON_0005445', 'segment of pes', 697, 'Autoimmune'), ('CL_0000066', 'epithelial cell', 827, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 827, 'epithelial'), ('CL_0000346', 'hair follicle dermal papilla cell', 943, 'dermal cells'), ('PR_000045358', 'insulin family protein', 965, 'Insulin'), ('CHEBI_28384', 'vitamin K', 1089, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1188, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1197, 'vitamin D'), ('UBERON_0002367', 'prostate gland', 1307, 'prostate'), ('UBERON_0000310', 'breast', 1324, 'breast'), ('UBERON_0012652', 'colorectum', 1342, 'colorectal')]	0	"['[""""caption (table-wrap): table 2\\n\\nfunctions diseases ceu yri signaturesceuyri diabetes 1.70e-172.70e-20 coronary artery disease 3.78e-173.12e-13 genetic disorder 1.09e-144.53e-14 cardiovascular disease 1.34e-144.78e-11sulin-dependent diabetes mellitus 1.03e-128.66e-15 endocrine system disorder 1.91e-121.25e-18 hypertension 2.13e-122.83e-11 neurological disorder 2.49e-123.27e-12 crohn*s disease 7.59e-127.25e-09 bipolar disease 3.50e-115.24e-09 metabolic disorder 5.66e-119.83e-16 inflammatory disorder 2.56e-091.08e-08 digestive system disorder 2.66e-091.31e-07 skeletal muscular disorder 1.49e-081.58e-08 progressive motor neuropathy 2.53e-085.59e-12 autoimmune disease 7.28e-081.09e-12 immunological disorder 2.46e-073.66e-13 rheumatoid arthritis 3.78e-072.54e-07 epithelial cells 8.86e-07 alzheimer*s disease 3.60e-062.27e-07 parkinson*s disease 7.24e-065.29e-06 dermal cells 9.33sulin-dependent diabetes mellitus 3.76e-15 neuropathy 5.38e-12 amyotrophic lateral sclerosis 1.36e-09 arthritis 1.44e-07\\n\\nvitamin hypothesis\\nan mcgrace [28] pitamin diseases sclerosis, diabetes, schizophrenia, prostate cancer, breast cancer colorectal cancer versatile normal development.""""]']"
S16-PMC3004407	PMC3004407	12/2010	S16-PMC3004407	['RATHER, Vitamin D is now seen as a preprohormone whose active Metabolites act not only to ensure Calcium Homeostasis and bone health [5] but also act as mediators of Immune function in general [6,7], and specific to Pregnancy, play a ROLE in Immune tolerance, Insulin resistance, and Preeclampsia [8–12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 234)]	2	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('CHEBI_25212', 'metabolite', 62, 'metabolites'), ('GO_0055073', 'cadmium ion homeostasis', 97, 'calcium homeostasis'), ('UBERON_0002405', 'immune system', 166, 'immune'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy'), ('UBERON_0002405', 'immune system', 242, 'immune'), ('PR_000045358', 'insulin family protein', 260, 'insulin'), ('GO_0007128', 'meiotic prophase I', 284, 'preeclampsia')]	0	['rather,  preprohormone whose metabolites ensure calcium homeostasis bone [5] immune [6,7], pregnancy, play immune tolerance,  resistance, preeclampsia [8–12].']
S155-PMC3366611	PMC3366611	4/2012	S155-PMC3366611	['a modest negative ASSOCIATION between maternal bmi and diet quality HAS BEEN IDENTIFIED [131], and obesity is ASSOCIATED with lower levels of Vitamin D [132] and Folic Acid levels during the Childbearing years [133], which MAY increase the risk of Insulin resistance and Neural Tube defects, respectively [134].']	[('SUPERFICIAL_RELATIONSHIP', 18), ('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 77), ('SUPERFICIAL_RELATIONSHIP', 110), ('INCOMPLETE_EVIDENCE', 223)]	5	[('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_30751', 'formic acid', 162, 'folic acid'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 191, 'childbearing'), ('PR_000045358', 'insulin family protein', 248, 'insulin'), ('UBERON_0001049', 'neural tube', 271, 'neural tube')]	0	['maternal bmi diet [131], obesity levels  [132] folic acid levels childbearing [133], increase  resistance neural tube defects, respectively [134].']
S14-PMC3427192	PMC3427192	4/2012	S14-PMC3427192	['Vitamin D overview\nVitamin D, a fat-soluble Nutrient, is a Secosteroid Hormone which is widely recognized as a modulator of calcium absorption and bone health and further Regulates Neuromuscular function, Cellular Differentiation, Insulin secretion, and Blood pressure.25,26vitamin D also plays an IMPORTANT ROLE in Immune Regulation through interactions between 1,25-Dihydroxyvitamin D and Vitamin D receptors ( vdrs ) .']	[('IMPORTANT_CONSIDERATION', 298), ('SUPERFICIAL_RELATIONSHIP', 308)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin'), ('CHEBI_28384', 'vitamin K', 19, 'Vitamin D'), ('CHEBI_33284', 'nutrient', 44, 'nutrient'), ('CHEBI_26661', 'shidasterone', 59, 'secosteroid hormone'), ('GO_0065007', 'biological regulation', 171, 'regulates'), ('UBERON_0001016', 'nervous system', 181, 'neuromuscular'), ('GO_0030154', 'cell differentiation', 205, 'cellular differentiation'), ('PR_000045358', 'insulin family protein', 231, 'insulin'), ('UBERON_0000178', 'blood', 254, 'blood'), ('PR_000006444', 'diacylglycerol kinase delta', 282, 'D'), ('UBERON_0002405', 'immune system', 316, 'immune'), ('GO_0065007', 'biological regulation', 323, 'regulation'), ('CHEBI_67472', '15-epi-lupulin B', 363, '1,25-dihydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 391, 'vitamin D')]	0	['vitamin overview\nvitamin d, fat-soluble nutrient, secosteroid hormone modulator calcium absorption bone neuromuscular function, cellular differentiation,  secretion, blood pressure.25,26vitamin plays immune 1,25-dihydroxyvitamin  receptors vdrs .']
S18-PMC3470091	PMC3470091	9/2012	S18-PMC3470091	['these CAN cause Vitamin D deficiency in mothers’ Milk as the only source of Vitamin D for babies.6\nthere are EVIDENCES SHOWING the ROLE of Vitamin D in keeping normal Glucose Homeostasis.7-10resistance to Insulin and destruction of Insulin secretion in Human and Animal MODELS has CONSIDERABLY been RELATED to Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 119), ('SUPERFICIAL_RELATIONSHIP', 131), ('INCOMPLETE_EVIDENCE', 270), ('ANOMALY_CURIOUS_FINDING', 281), ('SUPERFICIAL_RELATIONSHIP', 299)]	7	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0001913', 'milk', 49, 'milk'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_17234', 'glucose', 167, 'glucose'), ('GO_0042593', 'glucose homeostasis', 167, 'glucose homeostasis'), ('PR_000045358', 'insulin family protein', 205, 'insulin'), ('PR_000045358', 'insulin family protein', 232, 'insulin'), ('NCBITaxon_9606', 'Homo sapiens', 253, 'human'), ('NCBITaxon_33208', 'Metazoa', 263, 'animal'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin D')]	0	[' mothers’ milk  babies.6\nthere  keeping normal glucose homeostasis.7-10resistance  destruction  secretion human animal  deficiency.']
S19-PMC3470091	PMC3470091	9/2012	S19-PMC3470091	['such a RELATION HAS BEEN ATTRIBUTED to special receptors for Vitamin D in Pancreatic Betacells.9moreover, Vitamin D WAS SHOWN to have positive EFFECTS on Insulin sensitivity, and its deficiency to have negative EFFECTS on the function of Betacells.11IN AGREEMENT with this, cohort studies REVEALED that Vitamin D had a PROTECTIVE EFFECT against diabetes type Ii.8,11also, Serum concentration of Vitamin D during 24-29thweek of Pregnancy in women suffering from Gestational diabetes mellitus (gdm) was lower than that in women without the disease.12\nthe study of Vitamin D status and improving it in the Lactating mothers with previous gdm is of CONSPICUOUS VALUE.4,13\ndue to the limited exposure to sunshine and inadequate Intake, the level of Vitamin D is reduced in the milk of Lactating mothers.']	[('SUPERFICIAL_RELATIONSHIP', 7), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 143), ('SUPERFICIAL_RELATIONSHIP', 211), ('INCOMPLETE_EVIDENCE', 250), ('INCOMPLETE_EVIDENCE', 289), ('SUPERFICIAL_RELATIONSHIP', 319), ('SUPERFICIAL_RELATIONSHIP', 330), ('IMPORTANT_CONSIDERATION', 645)]	11	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CL_0000169', 'type B pancreatic cell', 74, 'pancreatic betacells'), ('UBERON_0001264', 'pancreas', 74, 'pancreatic'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('PR_000045358', 'insulin family protein', 154, 'insulin'), ('CL_0000365', 'animal zygote', 238, 'betacells'), ('CHEBI_27300', 'vitamin D', 303, 'vitamin D'), ('CL_0002212', 'type II muscle cell', 359, 'II'), ('UBERON_0001977', 'blood serum', 372, 'serum'), ('CHEBI_27300', 'vitamin D', 395, 'vitamin D'), ('GO_0007565', 'female pregnancy', 427, 'pregnancy'), ('GO_0007565', 'female pregnancy', 461, 'gestational'), ('CHEBI_27300', 'vitamin D', 562, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 603, 'lactating'), ('GO_0007631', 'feeding behavior', 723, 'intake'), ('CHEBI_27300', 'vitamin D', 744, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 780, 'lactating')]	0	['receptors  pancreatic betacells.9moreover,  positive  sensitivity, betacells.11in this,  diabetes type ii.8,11also, serum concentration  24-29thweek pregnancy women gestational diabetes mellitus (gdm) women disease.12\nthe  status lactating mothers gdm value.4,13\ndue exposure sunshine intake,  milk lactating mothers.']
S87-PMC3717170	PMC3717170	5/2013	S87-PMC3717170	['2; unpublished data) and improved MARKERS of adiposity and Vitamin D status (Plasma concentrations of Glucose, Insulin, adiponectin, 25(Oh)D3, 1,25(Oh)2D3, and pth), BUT an increased Plasma Ca2+.']	[('SUPERFICIAL_RELATIONSHIP', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 166)]	2	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 77, 'plasma'), ('CHEBI_17234', 'glucose', 102, 'glucose'), ('PR_000045358', 'insulin family protein', 111, 'insulin'), ('CHEBI_62946', 'ammonium sulfate', 133, '25(OH)D3'), ('CHEBI_73394', 'Ala-Ser', 145, '25(OH)2D3'), ('UBERON_0001969', 'blood plasma', 183, 'plasma'), ('CHEBI_29108', 'calcium(2+)', 190, 'Ca2+.')]	0	['2; data) adiposity  status (plasma concentrations glucose, adiponectin, 25(oh)d3, 1,25(oh)2d3, pth), plasma ca2+.']
S134-PMC3717170	PMC3717170	5/2013	S134-PMC3717170	['from a biological perspective, the HYPOTHESIS that Vitamin D MAY BE a DETERMINANT of diabetes risk is PLAUSIBLE, AS both impaired Insulin secretion and action HAVE BEEN reported with Vitamin D insufficiency.']	[('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 61), ('SUPERFICIAL_RELATIONSHIP', 70), ('INCOMPLETE_EVIDENCE', 102), ('PROBABLE_UNDERSTANDING', 113), ('INCOMPLETE_EVIDENCE', 159)]	6	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('PR_000045358', 'insulin family protein', 130, 'insulin'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D')]	0	['biological perspective,  diabetes plausible,  secretion  insufficiency.']
S43-PMC3760821	PMC3760821	9/2013	S43-PMC3760821	['further, it HAS BEEN SUGGESTED that Vitamin D CAN alter Glucose and Insulin Metabolism, and, THEREFORE, IMPACT on energy available to the foetus[11].']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 46), ('PROBABLE_UNDERSTANDING', 93), ('SUPERFICIAL_RELATIONSHIP', 104)]	4	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('GO_0007369', 'gastrulation', 56, 'glucose ...'), ('GO_1901142', 'insulin metabolic process', 68, 'insulin metabolism'), ('PR_000045358', 'insulin family protein', 68, 'insulin')]	0	['further,  alter glucose  metabolism, and, therefore, energy foetus[11].']
S44-PMC3760821	PMC3760821	9/2013	S44-PMC3760821	['there are numerous REPORTS SUPPORTING a ROLE for Vitamin D in promoting Insulin sensitivity and maintaining Glycaemic Control in t2dm, WHILE the EVIDENCE for a similar ROLE in t1dm is more LIMITED.']	[('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 40), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('INCOMPLETE_EVIDENCE', 145), ('SUPERFICIAL_RELATIONSHIP', 168), ('INCOMPLETE_EVIDENCE', 189)]	7	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('PR_000045358', 'insulin family protein', 72, 'insulin'), ('GO_0051162', 'L-arabitol metabolic process', 108, 'glycaemic control')]	0	[' promoting  sensitivity maintaining glycaemic t2dm, t1dm limited.']
S174-PMC3760821	PMC3760821	9/2013	S174-PMC3760821	['POTENTIAL mechanisms by which Vitamin D MIGHT INFLUENCE Glycaemic Control in t1dm include, the IMPACT of this Vitamin on Intracellular Calcium Regulation and, THUS, Glucose transport in target Tissues, INFLUENCES on Insulin receptor Expression and the EFFECT of Vitamin D on systemic inflammation ASSOCIATED with Insulin resistance[31],[32].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 95), ('PROBABLE_UNDERSTANDING', 159), ('SUPERFICIAL_RELATIONSHIP', 202), ('SUPERFICIAL_RELATIONSHIP', 252), ('SUPERFICIAL_RELATIONSHIP', 297)]	8	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0051162', 'L-arabitol metabolic process', 56, 'glycaemic control'), ('CHEBI_33229', 'vitamin (role)', 110, 'vitamin'), ('GO_0005622', 'intracellular anatomical structure', 121, 'intracellular'), ('GO_0006260', 'DNA replication', 121, 'intracellular'), ('GO_0051303', 'establishment of chromosome localization', 135, 'calcium regulation'), ('CHEBI_17234', 'glucose', 165, 'glucose'), ('UBERON_0000479', 'tissue', 193, 'tissues'), ('PR_000045358', 'insulin family protein', 216, 'insulin'), ('GO_0010467', 'gene expression', 233, 'expression'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D'), ('PR_000045358', 'insulin family protein', 313, 'insulin')]	0	['potential mechanisms  glycaemic t1dm include, vitamin intracellular calcium and, thus, glucose transport tissues,  receptor expression  systemic inflammation  resistance[31],[32].']
S176-PMC3760821	PMC3760821	9/2013	S176-PMC3760821	['low Vitamin D levels are ASSOCIATED with Insulin resistance in t2dm and its co-morbidities[35].']	[('SUPERFICIAL_RELATIONSHIP', 25)]	1	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('PR_000045358', 'insulin family protein', 41, 'insulin')]	0	['low  levels  resistance t2dm co-morbidities[35].']
S178-PMC3760821	PMC3760821	9/2013	S178-PMC3760821	['the results of a recent systematic review SUGGEST a weak EFFECT of Vitamin D supplementation in reducing fasting Glucose and improving Insulin resistance in patients with t2dm or impaired glucose tolerance[38].']	[('INCOMPLETE_EVIDENCE', 42), ('SUPERFICIAL_RELATIONSHIP', 57)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_17234', 'glucose', 113, 'glucose'), ('PR_000045358', 'insulin family protein', 135, 'insulin')]	0	['results  supplementation reducing fasting glucose  resistance patients t2dm glucose tolerance[38].']
S21-PMC3827489	PMC3827489	10/2013	S21-PMC3827489	['the wide variety of nonskeletal diseases in which Vitamin D is IMPORTANT include Cardiovascular diseases3), obesity4), Metabolic syndrome5), Insulin resistance6), infection7), allergy8,9), some forms of cancers10-12), and Autoimmune diseases13).']	[('IMPORTANT_CONSIDERATION', 63)]	1	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 81, 'cardiovascular'), ('GO_0008152', 'metabolic process', 119, 'metabolic'), ('PR_000045358', 'insulin family protein', 141, 'insulin'), ('UBERON_0001442', 'skeleton of manus', 222, 'autoimmune')]	0	['nonskeletal diseases  cardiovascular diseases3), obesity4), metabolic syndrome5),  resistance6), infection7), allergy8,9), forms cancers10-12), autoimmune diseases13).']
S83-PMC3827489	PMC3827489	10/2013	S83-PMC3827489	['studies have SUGGESTED that Vitamin D MAY directly Regulate Insulin secretion by binding to Pancreatic Β-Cell vdrs59), and MAY indirectly AFFECT Pancreatic Β-Cell function by Regulating Extracellular calcium concentrations59); these data SUGGEST that low Vitamin D levels MAY BE ASSOCIATED with Insulin resistance.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 38), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 138), ('INCOMPLETE_EVIDENCE', 238), ('INCOMPLETE_EVIDENCE', 272), ('SUPERFICIAL_RELATIONSHIP', 279)]	7	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0065007', 'biological regulation', 51, 'regulate'), ('PR_000045358', 'insulin family protein', 60, 'insulin'), ('CL_0000173', 'pancreatic D cell', 92, 'pancreatic β-cell'), ('UBERON_0001069', 'head of pancreas', 92, 'pancreatic β-'), ('CL_0000173', 'pancreatic D cell', 145, 'pancreatic β-cell'), ('UBERON_0001069', 'head of pancreas', 145, 'pancreatic β-'), ('GO_0065007', 'biological regulation', 175, 'regulating'), ('GO_0005576', 'extracellular region', 186, 'extracellular'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D'), ('PR_000045358', 'insulin family protein', 295, 'insulin')]	0	['studies  regulate  secretion binding pancreatic β-cell vdrs59), pancreatic β-cell extracellular calcium concentrations59);  levels  resistance.']
S86-PMC3827489	PMC3827489	10/2013	S86-PMC3827489	['moreover, a randomized clinical trial determining the efficacy of Vitamin D supplementation in obese adolescents SHOWED that supplementation of 4,000 iu Vitamin D3/day for 6 months significantly improved Insulin sensitivity60).']	[('INCOMPLETE_EVIDENCE', 113)]	1	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 153, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 153, 'vitamin D3'), ('PR_000045358', 'insulin family protein', 204, 'insulin')]	0	['moreover,  supplementation obese adolescents supplementation 4,000 iu vitamin d3/day 6 months  sensitivity60).']
S68-PMC3991049	PMC3991049	11/2013	S68-PMC3991049	['SEVERAL STUDIES have REPORTED ASSOCIATION between infant size and Vitamin D status.13,14reduced concentration of 25-Hydroxyvitamin D in mothers during late Pregnancy is ASSOCIATED with reduced Whole Body and Lumbar-Spine bone Mineral content in their children at the age of 9 years.15several studies HYPOTHESIZED that low Prenatal and Perinatal Vitamin D concentrations AFFECT the functional characteristics of various Tissues of the body, which leads to greater risk in later Life of multiple sclerosis, cancer, Insulin-dependent diabetes mellitus and schizophrenia.16,17\nthe current RECOMMENDED dose of Vitamin D during Pregnancy DIFFERS in DIFFERENT parts of the world.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 30), ('SUPERFICIAL_RELATIONSHIP', 169), ('INCOMPLETE_EVIDENCE', 300), ('SUPERFICIAL_RELATIONSHIP', 370), ('FUTURE_WORK', 585), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 632), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 643)]	9	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 113, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 156, 'pregnancy'), ('UBERON_0000468', 'multicellular organism', 193, 'whole body'), ('UBERON_0006074', 'lumbar region of vertebral column', 208, 'lumbar-spine'), ('CHEBI_46662', 'mineral', 226, 'mineral'), ('GO_0007565', 'female pregnancy', 322, 'prenatal'), ('GO_0036268', 'swimming', 335, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 335, 'perinatal'), ('CHEBI_27300', 'vitamin D', 345, 'vitamin D'), ('UBERON_0000479', 'tissue', 419, 'tissues'), ('UBERON_0000104', 'life cycle', 477, 'life'), ('PR_000045358', 'insulin family protein', 513, 'insulin'), ('CHEBI_27300', 'vitamin D', 605, 'vitamin D'), ('GO_0007565', 'female pregnancy', 622, 'pregnancy')]	0	['several infant  status.13,14reduced concentration 25-hydroxyvitamin mothers late pregnancy whole lumbar-spine bone mineral content children age 9 years.15several prenatal perinatal  concentrations functional characteristics tissues body, life sclerosis, cancer, -dependent diabetes mellitus schizophrenia.16,17\nthe dose  pregnancy parts world.']
S1375-PMC4113768	PMC4113768	7/2014	S1375-PMC4113768	['HOWEVER the mechanism is UNCLEAR, with studies examining the RELATIONSHIP between Vitamin D and Insulin resistance showing CONFLICTING results.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FULL_UNKNOWN', 25), ('SUPERFICIAL_RELATIONSHIP', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 123)]	4	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('PR_000045358', 'insulin family protein', 96, 'insulin')]	0	['however unclear,   resistance results.']
S1376-PMC4113768	PMC4113768	7/2014	S1376-PMC4113768	['we AIMED TO EXAMINE the ASSOCIATION between Vitamin D concentration and Insulin resistance in healthy, non-diabetic, overweight Individuals at high risk of Cardiovascular disease using gold-standard techniques for assessment of both Vitamin D concentration and Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('SUPERFICIAL_RELATIONSHIP', 24)]	3	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('PR_000045358', 'insulin family protein', 72, 'insulin'), ('NCBITaxon_1', 'root', 128, 'individuals'), ('UBERON_0004535', 'cardiovascular system', 156, 'cardiovascular'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('PR_000045358', 'insulin family protein', 261, 'insulin')]	0	[' concentration  resistance healthy, non-diabetic, overweight individuals cardiovascular disease using gold-standard techniques  concentration  resistance.']
S1386-PMC4113768	PMC4113768	7/2014	S1386-PMC4113768	['robust randomised controlled TRIALS ARE NEEDED to determine WHETHER improving Vitamin D status has a positive EFFECT on Insulin resistance OR OTHER pathophysiological indicators of dm including Beta-Cell function.']	[('FUTURE_WORK', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 60), ('SUPERFICIAL_RELATIONSHIP', 110), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 139), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 142)]	5	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('PR_000045358', 'insulin family protein', 120, 'insulin'), ('CL_0000349', 'extraembryonic cell', 194, 'beta-cell')]	0	['robust randomised  status positive  resistance pathophysiological dm beta-cell function.']
S3300-PMC4113768	PMC4113768	7/2014	S3300-PMC4113768	['there are many mechanisms whereby Vitamin D CAN reduce the RISK of cvd including reduced risk of diabetes mellitus and Metabolic syndrome, EFFECTS on Blood pressure, Cholesterol, cytokines, Endothelial disruption, Glucose Regulation, Insulin resistance, muscle strength, Respiratory infections, and vascular calcification.']	[('INCOMPLETE_EVIDENCE', 44), ('IMPORTANT_CONSIDERATION', 59), ('SUPERFICIAL_RELATIONSHIP', 139)]	3	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0008152', 'metabolic process', 119, 'metabolic'), ('UBERON_0000178', 'blood', 150, 'blood'), ('CHEBI_16113', 'cholesterol', 166, 'cholesterol'), ('UBERON_0001986', 'endothelium', 190, 'endothelial'), ('CHEBI_17234', 'glucose', 214, 'glucose'), ('GO_0006094', 'gluconeogenesis', 214, 'glucose regulation'), ('PR_000045358', 'insulin family protein', 234, 'insulin'), ('UBERON_0001004', 'respiratory system', 271, 'respiratory')]	0	['mechanisms whereby  cvd diabetes mellitus metabolic syndrome, blood pressure, cholesterol, cytokines, endothelial disruption, glucose regulation,  resistance, muscle strength, respiratory infections, vascular calcification.']
S0-PMC4427001	PMC4427001	4/2015	S0-PMC4427001	['Vitamin D status in women with Gestational diabetes mellitus during Pregnancy and Postpartum\n\nabstract\nof many Vitamin D Extraskeletal functions, its modulatory ROLE in Insulin secretion and action is ESPECIALLY RELEVANT for Gestational diabetes mellitus (gdm).']	[('SUPERFICIAL_RELATIONSHIP', 161), ('IMPORTANT_CONSIDERATION', 201), ('SUPERFICIAL_RELATIONSHIP', 212)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 31, 'Gestational'), ('GO_0007565', 'female pregnancy', 68, 'Pregnancy'), ('GO_0007567', 'parturition', 82, 'Postpartum'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 121, 'extraskeletal'), ('PR_000045358', 'insulin family protein', 169, 'insulin'), ('GO_0007565', 'female pregnancy', 225, 'gestational')]	0	['vitamin status women gestational diabetes mellitus pregnancy postpartum\n\nabstract\nof  extraskeletal functions, modulatory  secretion gestational diabetes mellitus (gdm).']
S24-PMC4427001	PMC4427001	4/2015	S24-PMC4427001	['furthermore, Vitamin D has a strong immunomodulatory EFFECT; it inhibits Angiogenesis [8] and is also INVOLVED in the Regulation of Insulin secretion and POSSIBLY Insulin action [11,12].']	[('SUPERFICIAL_RELATIONSHIP', 53), ('SUPERFICIAL_RELATIONSHIP', 102), ('INCOMPLETE_EVIDENCE', 154)]	3	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0001525', 'angiogenesis', 73, 'angiogenesis'), ('GO_0065007', 'biological regulation', 118, 'regulation'), ('PR_000045358', 'insulin family protein', 132, 'insulin'), ('PR_000045358', 'insulin family protein', 163, 'insulin')]	0	['furthermore,  immunomodulatory effect; inhibits angiogenesis [8]  secretion  [11,12].']
S92-PMC4427001	PMC4427001	4/2015	S92-PMC4427001	['the EFFECT of Vitamin D on Regulation Of Pancreatic Β Cell Function and Insulin secretion COULD BE MEDIATED through Intracellular changes in calcium pool.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 90), ('SUPERFICIAL_RELATIONSHIP', 99)]	3	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_1904353', 'regulation of telomere capping', 27, 'regulation of ... cell function'), ('CL_0005019', 'pancreatic epsilon cell', 41, 'pancreatic β cell'), ('UBERON_0001264', 'pancreas', 41, 'pancreatic'), ('PR_000045358', 'insulin family protein', 72, 'insulin'), ('GO_0005622', 'intracellular anatomical structure', 116, 'intracellular')]	0	[' pancreatic β cell  secretion intracellular changes calcium pool.']
S94-PMC4427001	PMC4427001	4/2015	S94-PMC4427001	['in addition, Vitamin D MAY also be NEEDED to ensure a normal rate of Calcium Flux Across Cell Membranes and maintenance of an adequate Cytosolic calcium pool, which is IMPORTANT for Insulin-mediated Intracellular Signalling in Insulin-responsive Tissues [35].']	[('INCOMPLETE_EVIDENCE', 23), ('FUTURE_WORK', 35), ('IMPORTANT_CONSIDERATION', 168)]	3	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_1990171', 'SCF complex disassembly in response to cadmium stress', 69, 'calcium flux across cell membranes'), ('GO_0005886', 'plasma membrane', 89, 'cell membranes'), ('GO_0005829', 'cytosol', 135, 'cytosolic'), ('PR_000045358', 'insulin family protein', 182, 'insulin'), ('GO_0005622', 'intracellular anatomical structure', 199, 'intracellular'), ('GO_0035556', 'intracellular signal transduction', 199, 'intracellular signalling'), ('PR_000045358', 'insulin family protein', 227, 'insulin'), ('UBERON_0000479', 'tissue', 246, 'tissues')]	0	['addition,  ensure normal rate calcium flux cell membranes maintenance cytosolic calcium pool, -mediated intracellular signalling -responsive tissues [35].']
S95-PMC4427001	PMC4427001	4/2015	S95-PMC4427001	['finally, SEVERAL STUDIES SUGGEST that Vitamin D COULD play a ROLE in the pathogenesis of diabetes mellitus type 2 by AFFECTING Insulin sensitivity of Β Cell function [36,37].']	[('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 61), ('SUPERFICIAL_RELATIONSHIP', 117)]	5	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('PR_000045358', 'insulin family protein', 127, 'insulin'), ('CL_0000570', 'parafollicular cell', 150, 'β cell')]	0	['finally,  play pathogenesis diabetes mellitus type 2  sensitivity β cell [36,37].']
S142-PMC4427001	PMC4427001	4/2015	S142-PMC4427001	['[44] assessed the EFFECT of Calcium and Vitamin D cosupplementation on gdm in a randomised placebo-controlled study (56 iranian women with gdm) and they OBSERVED a significant reduction in fpg, serum Insulin levels, and homa-ir and increase in quicki compared with placebo, and also an increase in Glutathione and a reduction in Serum ldl-Cholesterol and total Cholesterol and a significant elevation in hdl-Cholesterol were common.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('INCOMPLETE_EVIDENCE', 153)]	2	[('CHEBI_22313', 'alkaline earth metal atom', 28, 'calcium'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('PR_000045358', 'insulin family protein', 200, 'insulin'), ('CHEBI_16856', 'glutathione', 298, 'glutathione'), ('UBERON_0001977', 'blood serum', 329, 'serum'), ('CHEBI_16113', 'cholesterol', 339, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 361, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 408, 'cholesterol')]	0	['[44] calcium  cosupplementation gdm randomised placebo-controlled (56 iranian women gdm) reduction fpg, serum  levels, homa-ir increase quicki placebo, increase glutathione reduction serum ldl-cholesterol cholesterol elevation hdl-cholesterol common.']
S143-PMC4427001	PMC4427001	4/2015	S143-PMC4427001	['rudnicki and mølsted-pedersen [45] reported that supplementation with an active form of Vitamin D (1,25(Oh)2D) was ASSOCIATED with significant decrease of plasma Glucose level and POSSIBLE EFFECT on Insulin sensitivity.']	[('SUPERFICIAL_RELATIONSHIP', 115), ('INCOMPLETE_EVIDENCE', 180), ('SUPERFICIAL_RELATIONSHIP', 189)]	3	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_37958', 'dye', 99, '1,'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 101, '25(OH)2D'), ('CHEBI_17234', 'glucose', 162, 'glucose'), ('PR_000045358', 'insulin family protein', 199, 'insulin')]	0	['rudnicki mølsted-pedersen [45] supplementation form  (1,25(oh)2d) decrease plasma glucose  sensitivity.']
S153-PMC4427001	PMC4427001	4/2015	S153-PMC4427001	['POTENTIALLY beneficial EFFECT of Vitamin D supplementation and the PLAUSIBLE pathogenic ROLE of 25(Oh)D deficiency in the subsequent development of diabetes mellitus type 2 in women with gdm history HAS to be FURTHER explored considering the ROLE of Vitamin D in Modulating Insulin sensitivity and Glucose Metabolism.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 67), ('SUPERFICIAL_RELATIONSHIP', 88), ('IMPORTANT_CONSIDERATION', 199), ('FUTURE_WORK', 209), ('SUPERFICIAL_RELATIONSHIP', 242)]	7	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 96, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 250, 'vitamin D'), ('GO_0065007', 'biological regulation', 263, 'modulating'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('CHEBI_17234', 'glucose', 298, 'glucose'), ('GO_0006006', 'glucose metabolic process', 298, 'glucose metabolism')]	0	['potentially  supplementation pathogenic 25(oh)d diabetes mellitus type 2 women gdm   sensitivity glucose metabolism.']
S8-PMC4488777	PMC4488777	5/2015	S8-PMC4488777	['MOST experts agree that Vitamin D supplementation is a necessity, PARTICULARLY in women suffering from obesity, Insulin resistance or small Ovarian reserve, as well as in men with oligo- and asthenozoospermia if Serum concentration should fall below 50 nmol/l (normal range up to 125 nmol/l).']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 66)]	2	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('PR_000045358', 'insulin family protein', 112, 'insulin'), ('UBERON_0000992', 'ovary', 140, 'ovarian'), ('UBERON_0001977', 'blood serum', 212, 'serum')]	0	[' supplementation necessity, women obesity,  resistance ovarian reserve, men oligo- asthenozoospermia serum concentration fall 50 nmol/l (normal 125 nmol/l).']
S190-PMC4488777	PMC4488777	5/2015	S190-PMC4488777	['administration of Vitamin D is RECOMMENDED in the case of CONSIDERABLE deficiency, PARTICULARLY in obese, Insulin resistant women with low Amh levels, as well as in men with oligo- and asthenozoospermia.']	[('FUTURE_WORK', 31), ('IMPORTANT_CONSIDERATION', 58), ('IMPORTANT_CONSIDERATION', 83)]	3	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('PR_000045358', 'insulin family protein', 106, 'insulin'), ('CHEBI_16027', 'adenosine 5*-monophosphate', 139, 'AMH')]	0	['administration  deficiency, obese,  resistant women amh levels, men oligo- asthenozoospermia.']
S137-PMC4490503	PMC4490503	6/2015	S137-PMC4490503	['gdm develops when beta cell dysfunction coexists, and MAY BE characterised by further abnormalities in adipokine and cytokine profiles, increased Free Fatty Acids (ffa), Triglycerides (tg), low Vitamin D and Endothelial dysfunction.ijms-16-13442-t001_table 1\n\ncaption (table-wrap): table 1\n\nlongitudinal studies of inflammatory markers in prediction of gdm.inflammatory markerfirst author (year)study designgdm statusgdm diagnostic criteriagestational age at testing (weeks)EFFECT in gdmmatching or adjustment for confounderstnf-αkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter and coustan criteria [64]pre-gravid 12–14 weeks 34–36 weekstnf-Α ↑ 34–36 weeks in gdm inversely CORRELATED with Insulin sensitivityfat massgao (2008) [65]nested case-control22 gdm 10 igt 20 ngtunknown12–20 weeks 24–32 weekstnf-Α ↑ in gdm positively CORRELATED with bmi 14–20 weeksn/ageorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmisaucedo (2011) [67]prospective60 gdm 60 ngt24–28 weeks ada criteria 2010 [68]30 weeks 6 weeks 6 months Postpartumtnf-Α ↑ in both groups at 6 weeks Tnf-Α ↑ 6months Postpartum in gdmage weightlopez-tinoco (2012) [69]case-control63 gdm 63 ngt24–28 weeks nddg criteria [70]mean ~29 weekstnf-Α ↑ in gdmbmiguillemette (2014) [71]prospective61 gdm 695 ngt24–28 weeks iadpsg criteria [44]5–16 weeks 24–28 weekstnf-Α ↑ in both groups and ASSOCIATED with Insulin resistanceage bmi tg adiponectin.il-6morrisett (2011) [72]case-control20 gdm 27 ngt26.1 ± 3.7 weeks cda criteria [73]26.1 ± 3.7 weeks 8 weeks post-partumil-6 ↑ in gdm and post-Partum, CORRELATED with Insulin sensitivity and bmibmihassiakos (2015) [74]case-control40 gdm 94 ngt24–28 weeks iadpsg criteria [44]11–14 weekil-6 ↑ in gdm and inversely RELATED to Birth weightmaternal weightleptinkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter and coustan criteria [64]pre-gravid 12–14 weeks 34–36 weeksleptin ↑ across Pregnancy inverse CORRELATION with Insulin sensitivity, BUT non-significant when adjusted for fat massfat massgeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmiqiu (2004) [75]prospective47 gdm 776 ngt26–28 weeks carpenter and coustan criteria [64]13 weeks10-ng/ml ↑ in leptin ASSOCIATED with 20% ↑ gdmparity bmi family history of non-Insulin dependent diabetesadiponectingeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksage ethnicity gravidity parity bmimcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weekadiponectin ↓ gdm and offspringage maternal weightwilliams (2004) [77]nested case-control41 gdm 70 ngt26–28 weeks carpenter and coustan criteria [64]13 week4.6-fold ↑ risk of gdm if adiponectin < 6.4 mcg/ml, overweight women 11-fold ↑ risk of gdmbmilain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter and coustan criteria [64]9.3 ± 2.6 weeksadiponectin < 25th 11-fold ↑ risk gdmbmilowe (2010) [57]prospective1481 Pregnant women24–32 weeks 2 h 75 g ogtt unblinded if fpg > 5.8 mmol/l 2 h > 11.1 mmol/l or random Glucose ≥ 8.9 mmol/l24–32 weeks↓ adiponectin ASSOCIATED with ↑ Glucose and bmibmi c-peptide Gestation genderlacroix (2013) [79]prospective38 gdm 407 ngt24–28 weeks iadpsg criteria [44]6–13 week↓ adiponectin ASSOCIATED with ↑ risk gdm (or1.12 per 1 µg/ml ↓ of adiponectin) and ASSOCIATED with Insulin sensitivitybmi hba1cianniello (2013) [39]prospective16 gdm 32 ngt24–28 weeks carpenter and coustan criteria [64]all trimesters↓ adiponectin PREDICTIVE of gdm in overweight/obesen/aweerakiet (2006) [80]prospective60 gdm 299 ngt24–28 weeks carpenter and coustan criteria [64]21–27 weekadiponectin 10 µg/ml has sensitivity of 91% and specificity of 31% for gdmbmirbp-4krzyzanovska (2008) [81]nested case-control20 gdm 22 ngt24–28 weeks carpenter and coustan criteria [64]30 weekrbp-4 ↓ in gdmn/ananda (2013) [82]nested case-control60 gdm 240 ngt24–28 weeks who criteria 2006 [83]11–13 weeksno differencen/aabetew (2013) [84]nested case-control173 gdm 187 ngt24–28 weeks carpenter and coustan criteria [64]16 weeksrbp-4 ↑ in gdm BUT NOT significant after adjustmentmaternal age ethnicityresistinlain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter and coustan criteria [64]9.3 ± 2.6 weeksno differencebmigeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmilowe (2010) [57]prospective1481 Pregnant women24–32 weeks 2 h 75 g ogtt unblinded if fpg > 5.8 mmol/l 2 h > 11.1 mmol/l or Random Glucose ≥ 8.9 mmol/l24–32 weeksnot ASSOCIATED with Glucose or Birth weightbmi c-peptide Gestation gendernanda (2012) [85]nested case-control60 gdm 240 ngt24–28 weeks who criteria 2006 [83]11–13 weeksno differencen/amcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weeksresistin ↓ in gdm and offspringage maternal weightvisfatinkrzyzanovska (2006) [86]nested case-control64 gdm 30 ngt24–28 weeks carpenter and coustan criteria [64]28–30 weeks 38–40 weeks 2 weeks post-Partumvisfatin ↑ in gdmbmiferreira (2011) [87]case-control100 gdm 300 ngt24–28 weeks who criteria 2006 [83]11–13 weekvisfatin ↑ in gdmn/a\nngt = normal Glucose tolerance; igt = impaired Glucose tolerance; fpg = fasting plasma Glucose; homa-ir = homeostasis model assessment for Insulin resistance; matsuda index = measure of Insulin sensitivity; bmi = body mass index; tg = Triglycerides; n/a = not available; ↓ = decreased levels; ↑ = increased levels; adips = australasian diabetes in Pregnancy society; ada = american diabetes association; nddg = national diabetes data group; iadpsg = international association of diabetes and Pregnancy study group; cda = canadian diabetes association; who = world health organisation.']	[('INCOMPLETE_EVIDENCE', 54), ('SUPERFICIAL_RELATIONSHIP', 474), ('SUPERFICIAL_RELATIONSHIP', 689), ('SUPERFICIAL_RELATIONSHIP', 842), ('SUPERFICIAL_RELATIONSHIP', 1457), ('SUPERFICIAL_RELATIONSHIP', 1665), ('SUPERFICIAL_RELATIONSHIP', 1827), ('SUPERFICIAL_RELATIONSHIP', 2027), ('ANOMALY_CURIOUS_FINDING', 2065), ('SUPERFICIAL_RELATIONSHIP', 2387), ('SUPERFICIAL_RELATIONSHIP', 3275), ('SUPERFICIAL_RELATIONSHIP', 3437), ('SUPERFICIAL_RELATIONSHIP', 3506), ('SUPERFICIAL_RELATIONSHIP', 3670), ('ANOMALY_CURIOUS_FINDING', 4255), ('SUPERFICIAL_RELATIONSHIP', 4764)]	16	[('CHEBI_37958', 'dye', 146, 'free'), ('CHEBI_35366', 'fatty acid', 151, 'fatty acids'), ('CHEBI_17855', 'triglyceride', 170, 'triglycerides'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('UBERON_0001986', 'endothelium', 208, 'endothelial'), ('PR_000000034', 'BMP', 655, '-α'), ('PR_000045358', 'insulin family protein', 705, 'insulin'), ('PR_000000034', 'BMP', 819, '-α'), ('GO_0030254', 'protein secretion by the type III secretion system', 1131, 'postpartumTNF'), ('PR_000000034', 'BMP', 1144, '-α'), ('PR_000000134', 'tumor necrosis factor alpha', 1175, 'TNF-α'), ('GO_0007565', 'female pregnancy', 1191, 'postpartum'), ('PR_000000034', 'BMP', 1314, '-α'), ('PR_000000034', 'BMP', 1433, '-α'), ('PR_000045358', 'insulin family protein', 1473, 'insulin'), ('PR_000000035', 'BMP receptor type-1A', 1636, '-6'), ('GO_0007567', 'parturition', 1657, 'partum'), ('PR_000045358', 'insulin family protein', 1681, 'insulin'), ('PR_000000035', 'BMP receptor type-1A', 1801, '-6'), ('GO_0007567', 'parturition', 1838, 'birth'), ('GO_0007565', 'female pregnancy', 2009, 'pregnancy'), ('PR_000045358', 'insulin family protein', 2044, 'insulin'), ('PR_000045358', 'insulin family protein', 2445, 'insulin'), ('GO_0007565', 'female pregnancy', 3132, 'pregnant'), ('CHEBI_17234', 'glucose', 3230, 'glucose'), ('CHEBI_17234', 'glucose', 3293, 'glucose'), ('GO_0007565', 'female pregnancy', 3322, 'gestation'), ('PR_000045358', 'insulin family protein', 3522, 'insulin'), ('GO_0007565', 'female pregnancy', 4631, 'pregnant'), ('CHEBI_45267', 'praziquantel', 4722, 'random'), ('CHEBI_17234', 'glucose', 4729, 'glucose'), ('CHEBI_17234', 'glucose', 4780, 'glucose'), ('GO_0007567', 'parturition', 4791, 'birth'), ('GO_0007565', 'female pregnancy', 4817, 'gestation'), ('GO_0030164', 'protein denaturation', 5223, 'partumVisfatin'), ('CHEBI_17234', 'glucose', 5374, 'glucose'), ('CHEBI_17234', 'glucose', 5408, 'glucose'), ('CHEBI_17234', 'glucose', 5448, 'glucose'), ('PR_000045358', 'insulin family protein', 5500, 'insulin'), ('PR_000045358', 'insulin family protein', 5547, 'insulin'), ('CHEBI_17855', 'triglyceride', 5596, 'triglycerides'), ('GO_0007565', 'female pregnancy', 5709, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 5853, 'Pregnancy')]	0	['gdm develops beta cell dysfunction coexists, abnormalities adipokine cytokine profiles, fatty acids (ffa), triglycerides (tg),  endothelial dysfunction.ijms-16-13442-t001_table 1\n\ncaption (table-wrap): table 1\n\nlongitudinal inflammatory gdm.inflammatory markerfirst designgdm statusgdm diagnostic criteriagestational age testing (weeks)effect gdmmatching adjustment confounderstnf-αkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter coustan criteria [64]pre-gravid 12–14 weeks 34–36 weekstnf-α ↑ 34–36 weeks gdm  sensitivityfat massgao (2008) [65]nested case-control22 gdm 10 igt 20 ngtunknown12–20 weeks 24–32 weekstnf-α ↑ gdm positively bmi 14–20 weeksn/ageorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmisaucedo (2011) [67]prospective60 gdm 60 ngt24–28 weeks ada criteria 2010 [68]30 weeks 6 weeks 6 months postpartumtnf-α ↑ 6 weeks tnf-α ↑ 6months postpartum gdmage weightlopez-tinoco (2012) [69]case-control63 gdm 63 ngt24–28 weeks nddg criteria [70]mean ~29 weekstnf-α ↑ gdmbmiguillemette (2014) [71]prospective61 gdm 695 ngt24–28 weeks iadpsg criteria [44]5–16 weeks 24–28 weekstnf-α ↑  resistanceage bmi tg adiponectin.il-6morrisett (2011) [72]case-control20 gdm 27 ngt26.1 ± 3.7 weeks cda criteria [73]26.1 ± 3.7 weeks 8 weeks post-partumil-6 ↑ gdm post-partum,  sensitivity bmibmihassiakos (2015) [74]case-control40 gdm 94 ngt24–28 weeks iadpsg criteria [44]11–14 weekil-6 ↑ gdm birth weightmaternal weightleptinkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter coustan criteria [64]pre-gravid 12–14 weeks 34–36 weeksleptin ↑ pregnancy  sensitivity, non-significant adjusted fat massfat massgeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmiqiu (2004) [75]prospective47 gdm 776 ngt26–28 weeks carpenter coustan criteria [64]13 weeks10-ng/ml ↑ leptin 20% ↑ gdmparity bmi family non- diabetesadiponectingeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksage ethnicity gravidity parity bmimcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weekadiponectin gdm offspringage maternal weightwilliams (2004) [77]nested case-control41 gdm 70 ngt26–28 weeks carpenter coustan criteria [64]13 week4.6-fold ↑ gdm adiponectin 6.4 mcg/ml, overweight women 11-fold ↑ gdmbmilain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter coustan criteria [64]9.3 ± 2.6 weeksadiponectin 25th 11-fold ↑ gdmbmilowe (2010) [57]prospective1481 pregnant women24–32 weeks 2 h 75 g ogtt unblinded fpg > 5.8 mmol/l 2 h > 11.1 mmol/l random glucose ≥ 8.9 mmol/l24–32 weeks↓ adiponectin ↑ glucose bmibmi c-peptide gestation genderlacroix (2013) [79]prospective38 gdm 407 ngt24–28 weeks iadpsg criteria [44]6–13 week↓ adiponectin ↑ gdm (or1.12 µg/ml adiponectin)  sensitivitybmi hba1cianniello (2013) [39]prospective16 gdm 32 ngt24–28 weeks carpenter coustan criteria [64]all trimesters↓ adiponectin gdm overweight/obesen/aweerakiet (2006) [80]prospective60 gdm 299 ngt24–28 weeks carpenter coustan criteria [64]21–27 weekadiponectin 10 µg/ml sensitivity 91% specificity 31% gdmbmirbp-4krzyzanovska (2008) [81]nested case-control20 gdm 22 ngt24–28 weeks carpenter coustan criteria [64]30 weekrbp-4 gdmn/ananda (2013) [82]nested case-control60 gdm 240 ngt24–28 weeks criteria 2006 [83]11–13 weeksno differencen/aabetew (2013) [84]nested case-control173 gdm 187 ngt24–28 weeks carpenter coustan criteria [64]16 weeksrbp-4 ↑ gdm adjustmentmaternal age ethnicityresistinlain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter coustan criteria [64]9.3 ± 2.6 weeksno differencebmigeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmilowe (2010) [57]prospective1481 pregnant women24–32 weeks 2 h 75 g ogtt unblinded fpg > 5.8 mmol/l 2 h > 11.1 mmol/l random glucose ≥ 8.9 mmol/l24–32 weeksnot glucose birth weightbmi c-peptide gestation gendernanda (2012) [85]nested case-control60 gdm 240 ngt24–28 weeks criteria 2006 [83]11–13 weeksno differencen/amcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weeksresistin gdm offspringage maternal weightvisfatinkrzyzanovska (2006) [86]nested case-control64 gdm 30 ngt24–28 weeks carpenter coustan criteria [64]28–30 weeks 38–40 weeks 2 weeks post-partumvisfatin ↑ gdmbmiferreira (2011) [87]case-control100 gdm 300 ngt24–28 weeks criteria 2006 [83]11–13 weekvisfatin ↑ gdmn/a\nngt = normal glucose tolerance; igt = glucose tolerance; fpg = fasting plasma glucose; homa-ir = homeostasis  resistance; matsuda = measure  sensitivity; bmi = mass index; tg = triglycerides; n/a = available; = decreased levels; ↑ = levels; adips = australasian diabetes pregnancy society; ada = american diabetes association; nddg = national diabetes group; iadpsg = international diabetes pregnancy group; cda = canadian diabetes association; = world organisation.']
S293-PMC4490503	PMC4490503	6/2015	S293-PMC4490503	['Vitamin D\nlow Vitamin D HAS BEEN IMPLICATED in the aetiology of obesity, Insulin resistance and t2dm [121].']	[('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 33)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('PR_000045358', 'insulin family protein', 73, 'insulin')]	0	['vitamin d\nlow  aetiology obesity,  resistance t2dm [121].']
S1-PMC4600246	PMC4600246	10/2015	S1-PMC4600246	['RESEARCH HAS SHOWN that Vitamin K is an Anticalcification, anticancer, bone-forming and Insulin-sensitising Molecule.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 9)]	2	[('CHEBI_27300', 'vitamin D', 24, 'vitamin K'), ('GO_0009948', 'anterior/posterior axis specification', 40, 'anticalcification'), ('PR_000045358', 'insulin family protein', 88, 'insulin'), ('CHEBI_36357', 'polyatomic entity', 108, 'molecule')]	0	['research  anticalcification, anticancer, bone-forming -sensitising molecule.']
S24-PMC4600246	PMC4600246	10/2015	S24-PMC4600246	['Coronary Heart disease (chd)\nMAY reduce the RISK of chd, chd mortality and all-cause mortality52676\nInsulin sensitivity\nMAY help improve Insulin sensitivity40\nwarfarin international normalised ratio (inr)\nMAY help to stabilise inr in patients on warfarin41\nlow Vitamin K status (indicated by undercarboxylated mgp) is ASSOCIATED with increased vascular calcifications, and these levels CAN be improved by effective Vitamin K supplementation28–32it was long BELIEVED that Vitamin K was ONLY INVOLVED in forming Coagulation factors (ie, maintaining Haemostasis).']	[('INCOMPLETE_EVIDENCE', 29), ('IMPORTANT_CONSIDERATION', 44), ('INCOMPLETE_EVIDENCE', 120), ('INCOMPLETE_EVIDENCE', 205), ('SUPERFICIAL_RELATIONSHIP', 318), ('INCOMPLETE_EVIDENCE', 386), ('INCOMPLETE_EVIDENCE', 457), ('INCOMPLETE_EVIDENCE', 485), ('SUPERFICIAL_RELATIONSHIP', 490)]	9	[('UBERON_0002949', 'tectospinal tract', 0, 'Coronary heart'), ('PR_000045358', 'insulin family protein', 100, 'Insulin'), ('PR_000045358', 'insulin family protein', 137, 'insulin'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 415, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin K'), ('GO_0050817', 'coagulation', 510, 'coagulation'), ('GO_0007599', 'hemostasis', 547, 'haemostasis')]	0	['coronary disease (chd)\nmay chd, chd mortality all-cause mortality52676\n sensitivity\nmay  sensitivity40\nwarfarin international normalised ratio (inr)\nmay stabilise inr patients warfarin41\nlow  status (indicated undercarboxylated mgp) vascular calcifications, levels  supplementation28–32it  forming coagulation (ie, maintaining haemostasis).']
S65-PMC4600246	PMC4600246	10/2015	S65-PMC4600246	['this HAS BEEN SHOWN in one retrospective and two prospective studies.41\n\nVitamin K and Insulin sensitivity\nin a 3-year randomised, double-blind, controlled trial of 355 patients, Vitamin K significantly improved Insulin sensitivity in men with diabetes.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_28384', 'vitamin K', 73, 'Vitamin K'), ('PR_000045358', 'insulin family protein', 87, 'insulin'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin K'), ('PR_000045358', 'insulin family protein', 212, 'insulin')]	0	['studies.41\n\nvitamin k  sensitivity\nin 3-year randomised, double-blind, 355 patients,   sensitivity men diabetes.']
S68-PMC4600246	PMC4600246	10/2015	S68-PMC4600246	['IN SUMMARY, Vitamin K MAY improve Insulin sensitivity in men with diabetes.40\n\nVitamin K and cancer\nVitamin K2Has BEEN SHOWN to inhibit the growth of Human cancer cell lines, including Hepatoma lines, as well as to treat myelodysplastic syndrome.50–53two trials SEEM to INDICATE that Vitamin K245\u2005mg/day reduces the Development Of Hepatocellular Carcinoma (Hcc) in patients with Liver cirrhosis and that Vitamin K2Significantly reduces the recurrence of hcc in patients following the curative treatment of hcc with an ASSOCIATED reduction in all-cause mortality in these patients.54–61the POSSIBLE reduction in mortality with Vitamin K2May be EXPLAINED by multiple mechanisms.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 114), ('ANOMALY_CURIOUS_FINDING', 262), ('INCOMPLETE_EVIDENCE', 270), ('SUPERFICIAL_RELATIONSHIP', 518), ('INCOMPLETE_EVIDENCE', 589), ('PROBABLE_UNDERSTANDING', 643)]	8	[('CHEBI_27300', 'vitamin D', 12, 'vitamin K'), ('PR_000045358', 'insulin family protein', 34, 'insulin'), ('CHEBI_28384', 'vitamin K', 79, 'Vitamin K'), ('CHEBI_33229', 'vitamin (role)', 100, 'Vitamin'), ('PR_000009481', 'keratin, type II cytoskeletal 5', 108, 'K2has'), ('NCBITaxon_9606', 'Homo sapiens', 150, 'human'), ('UBERON_0004705', 'fenestra', 185, 'hepatoma'), ('CHEBI_86324', 'quinolone antibiotic', 284, 'vitamin K245'), ('GO_0002234', 'detection of endoplasmic reticulum overloading', 316, 'development of hepatocellular carcinoma'), ('UBERON_0012474', 'hepatic cecum', 331, 'hepatocellular'), ('GO_0000724', 'double-strand break repair via homologous recombination', 357, 'HCC'), ('UBERON_0002107', 'liver', 379, 'liver'), ('CHEBI_64387', 'thiosultap(1-)', 404, 'vitamin K2significantly'), ('CHEBI_27325', 'xanthophyll', 626, 'vitamin K2may'), ('PR_000017209', 'utrophin', 626, 'vitamin K2may')]	0	['summary,   sensitivity men diabetes.40\n\nvitamin k cancer\nvitamin k2has inhibit human cancer cell lines, hepatoma lines, treat myelodysplastic syndrome.50–53two vitamin k245\u2005mg/day reduces hepatocellular carcinoma (hcc) patients liver cirrhosis vitamin k2significantly reduces recurrence hcc patients following curative treatment hcc reduction all-cause mortality patients.54–61the reduction mortality vitamin k2may mechanisms.']
S77-PMC4600246	PMC4600246	10/2015	S77-PMC4600246	['finally, in the RECENT vitamin k italian (viki) dialysis STUDY, 23.5% of patients were FOUND to be Vitamin K deficient, and this deficiency was FOUND TO BE the strongest PREDICTOR of vertebral fractures (or: 2.94; 95% ci 1.38 to 6.26).72other data HAVE SHOWN that vitamin K2May improve Bone Remodelling in patients with haemodialysis with low Serum Parathyroid hormone levels.73supplementing with at LEAST 200\u2005µg Menaquinone-7 (a form of Vitamin K2) daily MAY help to achieve near maximal protection from vascular calcification, osteoporosis and cancer (measured by maximal gamma carboxylation of Vitamin K dependent proteins).35\n\nconclusion\nVitamin K has a plethora of POTENTIAL IMPLICATIONS, including prevention and treatment of Arterial calcifications, Coronary Heart disease and cancer, improvements in bone strength and reduced risks of fractures as well as improvements in Insulin sensitivity.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 57), ('INCOMPLETE_EVIDENCE', 87), ('ANOMALY_CURIOUS_FINDING', 144), ('SUPERFICIAL_RELATIONSHIP', 170), ('INCOMPLETE_EVIDENCE', 248), ('PROBABLE_UNDERSTANDING', 400), ('INCOMPLETE_EVIDENCE', 456), ('INCOMPLETE_EVIDENCE', 670), ('IMPORTANT_CONSIDERATION', 680)]	10	[('CHEBI_27300', 'vitamin D', 99, 'vitamin K'), ('PR_000009481', 'keratin, type II cytoskeletal 5', 272, 'K2may'), ('GO_0046849', 'bone remodeling', 286, 'bone remodelling'), ('UBERON_0001977', 'blood serum', 343, 'serum'), ('UBERON_0001132', 'parathyroid gland', 349, 'parathyroid'), ('CHEBI_18154', 'polysaccharide', 413, 'menaquinone'), ('CHEBI_28934', 'vitamin D2', 438, 'vitamin K2'), ('PR_000017299', 'VIP peptides', 438, 'vitamin K2'), ('CHEBI_27300', 'vitamin D', 597, 'vitamin K'), ('CHEBI_28384', 'vitamin K', 642, 'Vitamin K'), ('UBERON_0001637', 'artery', 732, 'arterial'), ('UBERON_0004151', 'cardiac chamber', 757, 'coronary heart'), ('PR_000045358', 'insulin family protein', 880, 'insulin')]	0	['finally, vitamin k italian (viki) dialysis study, 23.5% patients  deficient, vertebral fractures (or: 2.94; 95% ci 1.38 6.26).72other vitamin k2may bone remodelling patients haemodialysis serum parathyroid hormone levels.73supplementing 200\u2005µg menaquinone-7 (a form daily achieve maximal vascular calcification, osteoporosis cancer (measured maximal gamma carboxylation  proteins).35\n\nconclusion\nvitamin k implications, treatment arterial calcifications, coronary disease cancer, bone fractures  sensitivity.']
S85-PMC4613350	PMC4613350	9/2015	S85-PMC4613350	['matched for body mass index (bmi);6exclusion: Vitamin C and/or Vitamin E supplements, history of major medical complications, major fetal defects, repeated spontaneous abortion, use of an Illicit Drug or Warfarin treatment during the current Pregnancy;7inclusion: nulliparous women with singleton Pregnancies without major fetal chromosomal or structural anomaly;8exclusion: women who had a previous fetus with a chromosomal abnormality and women with Insulin-dependent diabetes mellitus;9exclusion: aids or hepatitis, cases of major fetal anomaly, fetal death and women with Placenta previa, Placenta accrete, or Placental abruption;10general population, singleton Pregnancies;11a priori high risk Pregnancies;12general population;13inclusion: singleton Pregnancy, exclusion: diabetes and chromosomal abnormalities;14exclusion: chronic Hepatic or Renal diseases, Pregnancies with major fetal abnormalities and those ending in termination, Miscarriage or fetal death <24 weeks;15exclusion : known aneuploidy and major congenital malformations;16exclusion: Miscarriages;17exclusion: congenital abnormalities or Medication use;18randomly selected controls;19exclusion: multifetal Gestation, diabetes, chromosomal or structural abnormalities;20exclusion: increased risk factors of pe, sga or ptb, known major fetal anomaly or abnormal karyotype, intervention that MAY modify Pregnancy outcome such as treatment with Aspirin or Progesterone;21inclusion: history of pe in a previous Pregnancy, chronic hypertension, chronic Renal disease, Antiphospholipid syndrome, systemic lupus erythematosus, Pregestational diabetes mellitus, obesity (bmi ≥ 30 kg/m2).']	[('INCOMPLETE_EVIDENCE', 1361)]	1	[('CHEBI_27300', 'vitamin D', 46, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin E'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 188, 'illicit drug'), ('CHEBI_10033', 'warfarin', 204, 'warfarin'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy'), ('GO_0007565', 'female pregnancy', 297, 'pregnancies'), ('PR_000045358', 'insulin family protein', 452, 'insulin'), ('UBERON_0001987', 'placenta', 576, 'placenta'), ('UBERON_0001987', 'placenta', 593, 'placenta'), ('UBERON_0001987', 'placenta', 614, 'placental'), ('GO_0007565', 'female pregnancy', 666, 'pregnancies'), ('GO_0007565', 'female pregnancy', 699, 'pregnancies'), ('GO_0007565', 'female pregnancy', 755, 'pregnancy'), ('UBERON_0002107', 'liver', 837, 'hepatic'), ('UBERON_0002113', 'kidney', 848, 'renal'), ('GO_0007565', 'female pregnancy', 864, 'pregnancies'), ('GO_0046660', 'female sex differentiation', 940, 'miscarriage'), ('GO_0042706', 'eye photoreceptor cell fate commitment', 1056, 'miscarriages'), ('CHEBI_60211', 'compound Z', 1110, 'medication'), ('GO_0007565', 'female pregnancy', 1178, 'gestation'), ('GO_0007565', 'female pregnancy', 1372, 'pregnancy'), ('CHEBI_2904', 'atenolol', 1413, 'aspirin'), ('CHEBI_17026', 'progesterone', 1424, 'progesterone'), ('GO_0007565', 'female pregnancy', 1478, 'pregnancy'), ('UBERON_0002113', 'kidney', 1519, 'renal'), ('CHEBI_16240', 'hydrogen peroxide', 1534, 'antiphospholipid'), ('GO_0007565', 'female pregnancy', 1591, 'pregestational')]	0	['matched mass (bmi);6exclusion:  and/or  supplements, medical complications, fetal defects, spontaneous abortion, illicit drug warfarin treatment pregnancy;7inclusion: nulliparous women singleton pregnancies fetal chromosomal structural anomaly;8exclusion: women fetus chromosomal abnormality women -dependent diabetes mellitus;9exclusion: hepatitis, cases fetal anomaly, fetal death women placenta previa, placenta accrete, placental abruption;10general population, singleton pregnancies;11a pregnancies;12general population;13inclusion: singleton pregnancy, exclusion: diabetes chromosomal abnormalities;14exclusion: chronic hepatic renal diseases, pregnancies fetal abnormalities ending termination, miscarriage fetal death <24 weeks;15exclusion : aneuploidy congenital malformations;16exclusion: miscarriages;17exclusion: congenital abnormalities medication use;18randomly selected controls;19exclusion: multifetal gestation, diabetes, chromosomal structural abnormalities;20exclusion: pe, sga ptb, fetal anomaly abnormal karyotype, pregnancy outcome treatment aspirin progesterone;21inclusion: pe pregnancy, chronic hypertension, chronic renal disease, antiphospholipid syndrome, systemic lupus erythematosus, pregestational diabetes mellitus, obesity (bmi ≥ 30 kg/m2).']
S116-PMC4632418	PMC4632418	10/2015	S116-PMC4632418	['there are MAJOR causes behind Vitamin D deficiency during Pregnancy, such as INADEQUATE exposure to sunlight, low Vitamin D intake and more REQUIREMENTS for Vitamin D. Vitamin D supplementation during Pregnancy has beneficial EFFECTS on glycaemia, Insulin sensitivity [45], Insulin resistance [46] and Metabolic profiles [47].']	[('IMPORTANT_CONSIDERATION', 10), ('IMPORTANT_CONSIDERATION', 77), ('IMPORTANT_CONSIDERATION', 140), ('SUPERFICIAL_RELATIONSHIP', 226)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 168, 'Vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy'), ('PR_000045358', 'insulin family protein', 248, 'insulin'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('GO_0008152', 'metabolic process', 302, 'metabolic')]	0	['behind  pregnancy, exposure sunlight,  intake . vitamin supplementation pregnancy glycaemia,  sensitivity [45],  resistance [46] metabolic [47].']
S84-PMC4684854	PMC4684854	12/2015	S84-PMC4684854	['obesity presents a CONFOUNDING INFLUENCE in THIS discussion, however, AS a greater bmi is ASSOCIATED with lower Vitamin D levels as well as greater Insulin resistance and risk for Gestational diabetes.']	[('PROBLEM_COMPLICATION', 19), ('SUPERFICIAL_RELATIONSHIP', 31), ('QUESTION_ANSWERED_BY_THIS_WORK', 44), ('PROBABLE_UNDERSTANDING', 70), ('SUPERFICIAL_RELATIONSHIP', 90)]	5	[('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('PR_000045358', 'insulin family protein', 148, 'insulin'), ('GO_0007565', 'female pregnancy', 180, 'gestational')]	0	['obesity presents discussion, however, bmi  levels  resistance gestational diabetes.']
S96-PMC4714725	PMC4714725	1/2016	S96-PMC4714725	['ab, a Micronutrients and Herbal supplements\nthere is NO CLEAR EVIDENCE that dietary supplementation with Vitamins, Minerals, herbs, or spices CAN improve diabetes, and there MAY BE safety CONCERNS regarding the long-term use of antioxidant supplements such as Vitamins E and C and Carotene.c Alcohol\nadults with diabetes who drink alcohol SHOULD do so in moderation (no more than one drink per day for Adult women and no more than two drinks per day for Adult men).c\nAlcohol Consumption MAY place People with diabetes at INCREASED risk for delayed hypoglycemia, ESPECIALLY IF taking Insulin or Insulin secretagogues.']	[('FULL_UNKNOWN', 53), ('PROBABLE_UNDERSTANDING', 56), ('INCOMPLETE_EVIDENCE', 142), ('INCOMPLETE_EVIDENCE', 174), ('PROBLEM_COMPLICATION', 188), ('FUTURE_WORK', 339), ('INCOMPLETE_EVIDENCE', 487), ('IMPORTANT_CONSIDERATION', 521), ('ANOMALY_CURIOUS_FINDING', 562), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 573)]	10	[('CHEBI_34850', 'milrinone lactate', 6, 'Micronutrients'), ('NCBITaxon_7955', 'Danio rerio', 25, 'herbal'), ('CHEBI_33277', 'gamma-tocotrienol', 105, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 115, 'minerals'), ('CHEBI_27300', 'vitamin D', 260, 'vitamins E'), ('CHEBI_18245', 'carboxylato group', 275, 'C'), ('PR_000004900', 'complement C3', 275, 'C'), ('CHEBI_23042', 'carotene', 281, 'carotene'), ('CHEBI_30879', 'alcohol', 292, 'Alcohol'), ('UBERON_0007023', 'adult organism', 402, 'adult'), ('UBERON_0007023', 'adult organism', 454, 'adult'), ('CHEBI_30879', 'alcohol', 467, 'Alcohol'), ('GO_0007631', 'feeding behavior', 475, 'consumption'), ('NCBITaxon_10088', 'Mus <genus>', 497, 'people'), ('PR_000045358', 'insulin family protein', 583, 'insulin'), ('PR_000045358', 'insulin family protein', 594, 'insulin')]	0	['ab, micronutrients herbal supplements\nthere dietary supplementation vitamins, minerals, herbs, spices diabetes, regarding long-term antioxidant supplements  c carotene.c alcohol\nadults diabetes drink alcohol moderation (no drink day adult women drinks day adult men).c\nalcohol consumption place people diabetes delayed hypoglycemia,  secretagogues.']
S112-PMC4778858	PMC4778858	3/2016	S112-PMC4778858	['INTERESTINGLY, Insulin sensitivity was significantly ASSOCIATED with maternal Serum Vitamin D level in univariate analysis.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 53)]	2	[('PR_000045358', 'insulin family protein', 15, 'insulin'), ('UBERON_0001977', 'blood serum', 78, 'serum'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]	0	['interestingly,  sensitivity maternal serum  univariate analysis.']
S31-PMC4785305	PMC4785305	3/2016	S31-PMC4785305	['in the middle east and north africa region, there are FEW RECENT rcts that attempted to determine the OPTIMAL regimen of Vitamin D replacement in healthy Pregnant women.38–41WITH the exception of soheilykhah et al 40who ASSESSED the EFFECT of Vitamin D supplementation on Insulin resistance, the primary outcomes in THESE studies were MOSTLY maternal and neonatal 25(Oh)D levels (seeonline supplementary appendix1).']	[('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 58), ('IMPORTANT_CONSIDERATION', 102), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 172), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 233), ('INCOMPLETE_EVIDENCE', 316), ('PROBABLE_UNDERSTANDING', 335)]	8	[('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('PR_000045358', 'insulin family protein', 272, 'insulin'), ('CHEBI_71657', 'versiconol acetate', 364, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 364, '25 ... OH ... D')]	0	['middle east north africa region, regimen  replacement healthy pregnant women.38–41with soheilykhah et al 40who  supplementation  resistance, outcomes maternal neonatal 25(oh)d levels (seeonline supplementary appendix1).']
S157-PMC4846845	PMC4846845	4/2016	S157-PMC4846845	['maternal Vitamin D levels during Pregnancy also PREDICT long-term outcomes for the child including congenital rickets, smaller Arm muscle and higher Insulin resistance, autism spectrum disorders, and asthma in childhood.']	[('SUPERFICIAL_RELATIONSHIP', 48)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('UBERON_0001460', 'arm', 127, 'arm'), ('PR_000045358', 'insulin family protein', 149, 'insulin')]	0	['maternal  levels pregnancy long-term outcomes child congenital rickets, arm muscle higher  resistance, autism spectrum disorders, asthma childhood.']
S158-PMC4846845	PMC4846845	4/2016	S158-PMC4846845	['higher levels of Vitamin D is ASSOCIATED with higher fasting Insulin, Cholesterol, and Triglyceride concentrations in Adults [120,121,122,123,124].']	[('SUPERFICIAL_RELATIONSHIP', 30)]	1	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('PR_000045358', 'insulin family protein', 61, 'insulin'), ('CHEBI_16113', 'cholesterol', 70, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 87, 'triglyceride'), ('UBERON_0007023', 'adult organism', 118, 'adults')]	0	['higher levels  higher fasting cholesterol, triglyceride concentrations adults [120,121,122,123,124].']
S110-PMC4934634	PMC4934634	11/2015	S110-PMC4934634	['low Vitamin D HAS BEEN ASSOCIATED with Insulin resistance.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 23)]	2	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('PR_000045358', 'insulin family protein', 39, 'insulin')]	0	['low   resistance.']
S116-PMC4934634	PMC4934634	11/2015	S116-PMC4934634	['the EFFECTS of Vitamin D supplementation (400 iu /day Vitamin D3) on Insulin and Glucose Metabolism were observed in healthy, Pregnant women in their 25th week of Gestation [45].']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 54, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 54, 'vitamin D3'), ('GO_0007631', 'feeding behavior', 69, 'insulin ...'), ('PR_000045358', 'insulin family protein', 69, 'insulin'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('GO_0006006', 'glucose metabolic process', 81, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 126, 'pregnant'), ('GO_0007565', 'female pregnancy', 163, 'gestation')]	0	[' supplementation (400 iu /day vitamin d3)  glucose metabolism healthy, pregnant women 25th week gestation [45].']
S122-PMC4934634	PMC4934634	11/2015	S122-PMC4934634	['improved Serum Insulin, Insulin resistance index (homa-ir), fasting Plasma Glucose, ldl and total Cholesterol were NOTED in the Vitamin D group compared to the placebo group.']	[('ANOMALY_CURIOUS_FINDING', 115)]	1	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('PR_000045358', 'insulin family protein', 15, 'insulin'), ('PR_000045358', 'insulin family protein', 24, 'insulin'), ('UBERON_0001969', 'blood plasma', 68, 'plasma'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('CHEBI_16113', 'cholesterol', 98, 'cholesterol'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]	0	['improved serum  resistance (homa-ir), fasting plasma glucose, ldl cholesterol  placebo group.']
S129-PMC4934634	PMC4934634	11/2015	S129-PMC4934634	['IN AGREEMENT WITH ANOTHER STUDY by the same group [45], Vitamin D plus calcium supplementation improved fasting Plasma Glucose, serum Insulin, homa-ir, hdl, and ldl in women with Gestational diabetes compared TO placebo.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 209)]	3	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 112, 'plasma'), ('CHEBI_17234', 'glucose', 119, 'glucose'), ('PR_000045358', 'insulin family protein', 134, 'insulin'), ('GO_0007565', 'female pregnancy', 179, 'gestational')]	0	['[45],  plus calcium supplementation fasting plasma glucose, serum homa-ir, hdl, ldl women gestational diabetes placebo.']
S147-PMC4949006	PMC4949006	7/2016	S147-PMC4949006	['it HAS BEEN IDENTIFIED as a Nutrient of PUBLIC HEALTH CONCERN by the us department of health and Human services.104\nNUMEROUS STUDIES HAVE SHOWN a prevalence of vitamin d levels of less than 50 nmol/l in 30% to 96% of Pregnant women, increasing with latitude and with nonwhite race.105–111a study done using archived samples of Cord Blood in denmark SHOWED an increased risk of developing schizophrenia with either elevated or low levels of Vitamin D. it was HYPOTHESIZED that IF all the infants COULD have been Born with normal levels there would have been a reduction of 43% in the incidence of schizophrenia among the Adults.112there is also an ASSOCIATION of Vitamin D deficiency and Insulin resistance,113which was reversed with a single injection of the vitamin114(not approved in the united states).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 40), ('INCOMPLETE_EVIDENCE', 116), ('INCOMPLETE_EVIDENCE', 133), ('INCOMPLETE_EVIDENCE', 349), ('INCOMPLETE_EVIDENCE', 458), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 476), ('INCOMPLETE_EVIDENCE', 495), ('SUPERFICIAL_RELATIONSHIP', 647)]	10	[('CHEBI_33284', 'nutrient', 28, 'nutrient'), ('NCBITaxon_10088', 'Mus <genus>', 97, 'Human'), ('GO_0007565', 'female pregnancy', 217, 'pregnant'), ('UBERON_0002240', 'spinal cord', 327, 'cord'), ('UBERON_0000178', 'blood', 332, 'blood'), ('CHEBI_28384', 'vitamin K', 440, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 440, 'Vitamin D'), ('GO_0007567', 'parturition', 511, 'born'), ('UBERON_0007023', 'adult organism', 620, 'adults'), ('CHEBI_27300', 'vitamin D', 662, 'vitamin D'), ('PR_000045358', 'insulin family protein', 687, 'insulin')]	0	['nutrient us department human services.104\nnumerous vitamin levels 50 nmol/l 30% 96% pregnant women, latitude nonwhite race.105–111a done using archived samples cord blood denmark schizophrenia levels vitamin d. infants born normal levels reduction 43% schizophrenia among adults.112there   resistance,113which single injection vitamin114(not approved united states).']
S9-PMC5035678	PMC5035678	4/2016	S9-PMC5035678	['conclusions\nALTHOUGH the high Vitamin D supplementation dose in the PRESENT STUDY (compared to the 400 iu/day dose USUALLY recommended for Pregnancy) SAFELY increases the Serum 25Ohd, in gdm cases, the higher dose does not affect the plasma Glucose level or Insulin resistance at short term follow-up after Delivery.']	[('ANOMALY_CURIOUS_FINDING', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 68), ('INCOMPLETE_EVIDENCE', 115), ('IMPORTANT_CONSIDERATION', 150)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 177, '25OHD'), ('CHEBI_17234', 'glucose', 241, 'glucose'), ('PR_000045358', 'insulin family protein', 258, 'insulin'), ('GO_0007567', 'parturition', 307, 'delivery')]	0	['conclusions\nalthough  supplementation dose (compared 400 iu/day dose pregnancy) serum 25ohd, gdm cases, higher dose plasma glucose  resistance term follow-up delivery.']
S23-PMC5035678	PMC5035678	4/2016	S23-PMC5035678	['a RECENT STUDY SHOWED that post-Parturition Vitamin D supplementation MAY PREVENT the progression of Insulin resistance in patients with a recent history of gdm (16).']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 70), ('SUPERFICIAL_RELATIONSHIP', 74)]	4	[('GO_0019230', 'proprioception', 32, 'parturition'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('PR_000045358', 'insulin family protein', 101, 'insulin')]	0	['post-parturition  supplementation progression  resistance patients gdm (16).']
S26-PMC5035678	PMC5035678	4/2016	S26-PMC5035678	['objectives\nwe THEREFORE SOUGHT TO EXPLORE the EFFECT of Vitamin D supplementation in women with gdm and hypovitaminosis D, both on post-Partum Glucose levels and Insulin resistance, in a randomized clinical trial.']	[('PROBABLE_UNDERSTANDING', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('SUPERFICIAL_RELATIONSHIP', 46)]	4	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('GO_0007567', 'parturition', 136, 'partum'), ('CHEBI_17234', 'glucose', 143, 'glucose'), ('PR_000045358', 'insulin family protein', 162, 'insulin')]	0	['objectives\nwe  supplementation women gdm hypovitaminosis d, post-partum glucose levels  resistance, trial.']
S110-PMC5035678	PMC5035678	4/2016	S110-PMC5035678	['OUR STUDY DEMONSTRATES that high dose Vitamin D supplementation during Pregnancy in women with gdm and impairment of 25Ohd concentration has no effect on post-Partum Plasma Glucose and Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10)]	2	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 117, '25OHD'), ('GO_0007567', 'parturition', 159, 'partum'), ('UBERON_0001969', 'blood plasma', 166, 'plasma'), ('CHEBI_17234', 'glucose', 173, 'glucose'), ('PR_000045358', 'insulin family protein', 185, 'insulin')]	0	['dose  supplementation pregnancy women gdm impairment 25ohd concentration post-partum plasma glucose  resistance.']
S113-PMC5035678	PMC5035678	4/2016	S113-PMC5035678	['several observational STUDIES INDICATE that Serum 25Ohd has an inverse RELATIONSHIP with Insulin resistance and incidence of gdm (22,23), and that Vitamin D deficiency is ASSOCIATED with type 2 diabetes (24).']	[('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 71), ('SUPERFICIAL_RELATIONSHIP', 171)]	4	[('UBERON_0001977', 'blood serum', 44, 'serum'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 50, '25OHD'), ('PR_000045358', 'insulin family protein', 89, 'insulin'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D')]	0	['several serum 25ohd  resistance gdm (22,23),  type 2 diabetes (24).']
S114-PMC5035678	PMC5035678	4/2016	S114-PMC5035678	['in addition, Animal studies have DEMONSTRATED that Vitamin D deficiency causes Insulin secretion defects (25).']	[('INCOMPLETE_EVIDENCE', 33)]	1	[('NCBITaxon_33208', 'Metazoa', 13, 'animal'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('PR_000045358', 'insulin family protein', 79, 'insulin')]	0	['addition, animal  causes  secretion defects (25).']
S117-PMC5035678	PMC5035678	4/2016	S117-PMC5035678	['(26) REVEALED a positive EFFECT of co-supplementation with Vitamin D and Calcium on Insulin resistance during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 25)]	2	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 73, 'calcium'), ('PR_000045358', 'insulin family protein', 84, 'insulin'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy')]	0	['(26) positive co-supplementation  calcium  resistance pregnancy.']
S128-PMC5035678	PMC5035678	4/2016	S128-PMC5035678	['(28) FOUND that 1000 mg elemental Calcium plus 400 iu Vitamin D daily, in middle age and elderly women for a median of 7 years, did not reduce the incidence of diabetes and Insulin resistance.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_22313', 'alkaline earth metal atom', 34, 'calcium'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('PR_000045358', 'insulin family protein', 173, 'insulin')]	0	['(28) 1000 mg elemental calcium plus 400 iu  daily, middle age elderly women median 7 years, diabetes  resistance.']
S132-PMC5035678	PMC5035678	4/2016	S132-PMC5035678	['they FOUND that high dose supplementation for a mean of 14 weeks during Pregnancy was not beneficial to the patients’ plasma Glucose level or Insulin resistance during Pregnancy, BUT that their babies BENEFITTED from the supplementation with decreased neonatal hypovitaminosis D. the authors CONCLUDED that the commencement of Vitamin D supplementation MAY HAVE been too late to cause any observable EFFECTS on Β-Cell function, and they SUGGESTED that earlier supplementation, EVEN before Pregnancy, MIGHT be EFFECTIVE.']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179), ('IMPORTANT_CONSIDERATION', 201), ('INCOMPLETE_EVIDENCE', 292), ('INCOMPLETE_EVIDENCE', 353), ('IMPORTANT_CONSIDERATION', 357), ('SUPERFICIAL_RELATIONSHIP', 400), ('INCOMPLETE_EVIDENCE', 437), ('ANOMALY_CURIOUS_FINDING', 477), ('INCOMPLETE_EVIDENCE', 500), ('SUPERFICIAL_RELATIONSHIP', 509)]	11	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('PR_000045358', 'insulin family protein', 142, 'insulin'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 277, 'D'), ('CHEBI_27300', 'vitamin D', 327, 'vitamin D'), ('CL_0000623', 'natural killer cell', 411, 'β-cell'), ('GO_0007565', 'female pregnancy', 489, 'pregnancy')]	0	['dose supplementation 14 weeks pregnancy patients’ plasma glucose  resistance pregnancy, babies supplementation decreased neonatal hypovitaminosis d. authors commencement  supplementation late β-cell function, supplementation, pregnancy, effective.']
S133-PMC5035678	PMC5035678	4/2016	S133-PMC5035678	['in OUR STUDY, over a median interval of 26 weeks between commencement of Vitamin D supplements and ogtt measurements, high dose Vitamin D LED TO maternal and neonatal 25Ohd level increases, but not to the predicted EFFECTS on Glucose level and Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 138), ('SUPERFICIAL_RELATIONSHIP', 215)]	3	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 167, '25OHD'), ('CHEBI_17234', 'glucose', 226, 'glucose'), ('PR_000045358', 'insulin family protein', 244, 'insulin')]	0	['study, median interval 26 weeks commencement  supplements ogtt measurements, dose  maternal neonatal 25ohd increases, glucose  resistance.']
S137-PMC5035678	PMC5035678	4/2016	S137-PMC5035678	['(30) REPORTED that daily 4,000 iu Vitamin D3 supplementation for 6 months (720,000 iu total) significantly decreased Insulin resistance in south asian women with Vitamin D deficiency and Insulin resistance.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_33279', 'vitamin D5', 34, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 34, 'vitamin D3'), ('PR_000045358', 'insulin family protein', 117, 'insulin'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('PR_000045358', 'insulin family protein', 187, 'insulin')]	0	['(30) daily 4,000 iu vitamin d3 supplementation 6 months (720,000 iu total) decreased  resistance south asian women   resistance.']
S143-PMC5035678	PMC5035678	4/2016	S143-PMC5035678	['in ANOTHER STUDY of the non-Pregnant population, and CONSISTENT with our results, davidson and colleagues FOUND that a mean supplement dose of 88,865 iu Vitamin D per week, in 56 subjects with hypovitaminosis D and pre-diabetes, had no effect on Insulin resistance and plasma Glucose levels at 3, 6, 9, and 12 months after intervention, compared to 53 subjects in a placebo group (31).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 106)]	3	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 209, 'D'), ('PR_000045358', 'insulin family protein', 246, 'insulin'), ('CHEBI_17234', 'glucose', 276, 'glucose')]	0	['non-pregnant population, results, davidson colleagues supplement dose 88,865 iu  week, 56 subjects hypovitaminosis pre-diabetes,  resistance plasma glucose levels 3, 6, 9, 12 months intervention, 53 subjects placebo (31).']
S147-PMC5035678	PMC5035678	4/2016	S147-PMC5035678	['as PREVIOUSLY discussed, a LIMITED NUMBER OF STUDIES have evaluated the EFFECT of Vitamin D on Glucose Metabolism and Insulin resistance, especially during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 72)]	4	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0006006', 'glucose metabolic process', 95, 'glucose metabolism'), ('PR_000045358', 'insulin family protein', 118, 'insulin'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy')]	0	['discussed,  glucose metabolism  resistance, pregnancy.']
S150-PMC5035678	PMC5035678	4/2016	S150-PMC5035678	['the study was DESIGNED to detect any EFFECTS of Vitamin D on Insulin resistance by allowing for adequate time between the start of supplementation and the measurement of outcomes, and with the FEWEST number of patients lost to follow up.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 193)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('PR_000045358', 'insulin family protein', 61, 'insulin')]	0	['  resistance allowing supplementation outcomes, patients up.']
S170-PMC5118763	PMC5118763	12/2016	S170-PMC5118763	['there is SOME EVIDENCE that high maternal Folate status in combination with low Vitamin B-12 status MAY increase the risk of obesity and Insulin resistance in the offspring (21).']	[('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 100)]	2	[('CHEBI_30863', '5-azaorotic acid', 42, 'folate'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 80, 'vitamin B-12'), ('PR_000045358', 'insulin family protein', 137, 'insulin')]	0	['maternal folate status combination -12 status increase obesity  resistance offspring (21).']
S22-PMC5129897	PMC5129897	10/2016	S22-PMC5129897	['diseases included in THIS STUDY along with a brief overview of the mechanisms of Vitamin D for each disease and a listing of a few observational studies and clinical trials in support.diseasemechanismsobservational studiesclinical trialscancereffects on cells, Angiogenesis, and metastasis10breast and Colorectal cancer incidence11; survival12breast and all-cancer incidence13cvdeffects on Serum Cholesterol levels, Arterial stiffness, Insulin resistance, hyperglycemia, and increased incident Metabolic syndrome are POTENTIALLY PLAUSIBLE mediators8refs.14,15effect on cvd risk factors16dementiaregulation of Calcium Homeostasis, clearance of Amyloid-Β peptide, antioxidant and anti-inflammatory EFFECTS, and POSSIBLE protection against the neurodegenerative mechanisms ASSOCIATED with ad17incidence18\xa0dmimproves Insulin sensitivity and secretion, mainly via its anti-inflammatory properties19incidence20; meta-analysis21\xa0falls and fracturesreduces bone mass loss by reducing inflammation22; maintains cognition23; helps maintain muscle mass24ref.25ref.26mseffects on Regulatory T and B Cells27Ref.28\xa0respiratory infectionsinduction of Cathelicidin and defensins29; strengthens Adaptive and innate Immune System30Pneumonia31Influenza32,33; ari34\nad, alzheimer disease; ari, acute Respiratory Tract infection; cvd, Cardiovascular disease; dm, diabetes mellitus; ms, multiple sclerosis.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('INCOMPLETE_EVIDENCE', 517), ('INCOMPLETE_EVIDENCE', 529), ('SUPERFICIAL_RELATIONSHIP', 696), ('INCOMPLETE_EVIDENCE', 709), ('SUPERFICIAL_RELATIONSHIP', 770)]	6	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0001525', 'angiogenesis', 261, 'angiogenesis'), ('UBERON_0012652', 'colorectum', 302, 'colorectal'), ('UBERON_0001977', 'blood serum', 390, 'serum'), ('CHEBI_16113', 'cholesterol', 396, 'cholesterol'), ('UBERON_0001637', 'artery', 416, 'arterial'), ('PR_000045358', 'insulin family protein', 436, 'insulin'), ('GO_0008152', 'metabolic process', 494, 'metabolic'), ('GO_0055073', 'cadmium ion homeostasis', 609, 'calcium homeostasis'), ('PR_000004519', 'autism susceptibility gene 2 protein', 643, 'amyloid-β'), ('PR_000045358', 'insulin family protein', 813, 'insulin'), ('CL_0000815', 'regulatory T cell', 1068, 'regulatory T ...'), ('GO_0065007', 'biological regulation', 1068, 'regulatory'), ('CL_0000960', 'T3 B cell', 1085, 'B cells27Ref'), ('PR_000006009', 'alpha-catulin', 1136, 'cathelicidin'), ('GO_0051886', 'negative regulation of timing of anagen', 1178, 'adaptive ...'), ('UBERON_0003822', 'forelimb stylopod', 1198, 'immune system30Pneumonia31Influenza32'), ('UBERON_0000065', 'respiratory tract', 1280, 'respiratory tract'), ('UBERON_0004535', 'cardiovascular system', 1314, 'cardiovascular')]	0	['diseases along mechanisms  disease listing support.diseasemechanismsobservational studiesclinical trialscancereffects cells, angiogenesis, metastasis10breast colorectal cancer incidence11; survival12breast all-cancer incidence13cvdeffects serum cholesterol levels, arterial stiffness,  resistance, hyperglycemia, incident metabolic syndrome mediators8refs.14,15effect cvd factors16dementiaregulation calcium homeostasis, clearance amyloid-β peptide, antioxidant anti-inflammatory effects, neurodegenerative mechanisms ad17incidence18\xa0dmimproves  sensitivity secretion, via anti-inflammatory properties19incidence20; meta-analysis21\xa0falls fracturesreduces bone mass loss reducing inflammation22; cognition23; maintain muscle mass24ref.25ref.26mseffects b cells27ref.28\xa0respiratory infectionsinduction cathelicidin defensins29; adaptive innate immune system30pneumonia31influenza32,33; ari34\nad, alzheimer disease; ari, acute respiratory tract infection; cvd, cardiovascular disease; dm, diabetes mellitus; ms, sclerosis.']
S112-PMC5359891	PMC5359891	3/2017	S112-PMC5359891	['secondary maternal outcomes of the initial phase of the nipper study are:\nmaintenance of a healthy Pregnancy, including normal duration of Gestation (at least 37\xa0weeks’ Gestation), absence of gdm (defined using the international association of the diabetes and Pregnancy study groups criteria: Glucose cut-off values of ≥5.1\xa0mmol/l for fasting Plasma Glucose, and/or ≥10.0\xa0mmol/l for 1-h and/or ≥8.5\xa0mmol/l for 2-h post load), change in fasting Glucose and ogtt Glucose area under the curve from Preconception baseline to 28\xa0weeks’ Gestation, maternal wellbeing/mood, absence of excessive nausea and vomiting, adequate Pregnancy weight gain (institute of medicine criteria) and Vaginal Delivery rates\nreduction in maternal Micronutrient insufficiency, specifically less riboflavin, Vitamin B6, Vitamin B12, zinc and Vitamin D insufficiency, before and during Pregnancy\nalteration in Gut microbiota CONSISTENT with enhanced wellbeing\nalteration in maternal metabolomic and epigenetic biomarkers CONSISTENT with improved maternal and/or offspring wellbeing\nenhancement of Breast Milk Micronutrient content, altered Immunological factors, epigenetic and metabolomic profiles (subsample) and maintenance of healthy Lactogenesis\nsecondary offspring outcomes of the initial phase of the nipper study are:\nneonatal adiposity measured by pea pod\nBirthweight 2500–4000\xa0g, size for Gestational age at Birth and customised birthweight centile\nreduced adiposity gain during Infancy, analysed taking account of infant Feeding\nreduction in Cord Blood c-peptide as a marker of overall glycaemia during Gestation\npromotion of offspring wellbeing and healthy Cardiometabolic RISK FACTORS, including Visceral adiposity and markers of Insulin resistance, during infancy\nalteration in offspring metabolomic and epigenetic biomarkers in Perinatal samples, CONSISTENT with improved infant Metabolic and allergic Wellbeing\nalteration in Gut microbiota to a microbiota ASSOCIATED with infant Metabolic and allergic Wellbeing\n\ndata and biosample collection\nstudy data will be collected by trained research staff using an access-controlled, web-based database (medscinet, stockholm) managed with support from the data management staff of the mrc Lifecourse epidemiology unit and the singapore institute for clinical sciences.']	[('INCOMPLETE_EVIDENCE', 898), ('INCOMPLETE_EVIDENCE', 994), ('SUPERFICIAL_RELATIONSHIP', 1658), ('INCOMPLETE_EVIDENCE', 1835), ('SUPERFICIAL_RELATIONSHIP', 1945)]	5	[('GO_0007565', 'female pregnancy', 99, 'pregnancy'), ('GO_0007565', 'female pregnancy', 139, 'gestation'), ('GO_0007565', 'female pregnancy', 169, 'gestation'), ('GO_0007565', 'female pregnancy', 261, 'Pregnancy'), ('CHEBI_17234', 'glucose', 294, 'glucose'), ('UBERON_0001969', 'blood plasma', 344, 'plasma'), ('CHEBI_17234', 'glucose', 351, 'glucose'), ('CHEBI_17234', 'glucose', 445, 'glucose'), ('CHEBI_17234', 'glucose', 462, 'glucose'), ('GO_0007565', 'female pregnancy', 496, 'preconception'), ('GO_0007565', 'female pregnancy', 532, 'gestation'), ('GO_0007565', 'female pregnancy', 619, 'pregnancy'), ('UBERON_0001987', 'placenta', 678, 'vaginal'), ('GO_0007567', 'parturition', 686, 'delivery'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 723, 'micronutrient'), ('CHEBI_33237', 'vitamin D4', 782, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 794, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 816, 'vitamin D'), ('GO_0007565', 'female pregnancy', 859, 'pregnancy'), ('UBERON_0001555', 'digestive tract', 883, 'gut'), ('UBERON_0001348', 'brown adipose tissue', 1070, 'breast milk'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1082, 'micronutrient'), ('UBERON_0003222', 'flexor digitorum superficialis', 1113, 'immunological'), ('GO_0001554', 'luteolysis', 1211, 'lactogenesis'), ('GO_0007608', 'sensory perception of smell', 1338, 'Birthweight'), ('GO_0007565', 'female pregnancy', 1372, 'gestational'), ('GO_0007567', 'parturition', 1391, 'birth'), ('UBERON_0000023', 'wing', 1462, 'infancy'), ('GO_0007631', 'feeding behavior', 1505, 'feeding'), ('UBERON_0002240', 'spinal cord', 1526, 'cord'), ('UBERON_0000178', 'blood', 1531, 'blood'), ('GO_0007565', 'female pregnancy', 1587, 'gestation'), ('GO_0007599', 'hemostasis', 1642, 'cardiometabolic'), ('UBERON_0002075', 'viscus', 1682, 'visceral'), ('PR_000045358', 'insulin family protein', 1716, 'insulin'), ('GO_0036268', 'swimming', 1816, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1816, 'perinatal'), ('GO_0051238', 'sequestering of metal ion', 1867, 'metabolic ... wellbeing'), ('UBERON_0001555', 'digestive tract', 1914, 'gut'), ('GO_0051238', 'sequestering of metal ion', 1968, 'metabolic ... wellbeing'), ('UBERON_0001281', 'hepatic sinusoid', 2220, 'Lifecourse')]	0	['secondary maternal outcomes phase are:\nmaintenance healthy pregnancy, normal duration gestation (at 37\xa0weeks’ gestation), absence gdm (defined using international diabetes pregnancy criteria: glucose cut-off values ≥5.1\xa0mmol/l fasting plasma glucose, and/or ≥10.0\xa0mmol/l 1-h and/or ≥8.5\xa0mmol/l 2-h post load), fasting glucose ogtt glucose curve preconception baseline 28\xa0weeks’ gestation, maternal wellbeing/mood, absence excessive nausea vomiting, pregnancy gain (institute medicine criteria) vaginal delivery rates\nreduction maternal micronutrient insufficiency, riboflavin, vitamin b6, vitamin b12, zinc  insufficiency, pregnancy\nalteration gut microbiota wellbeing\nalteration maternal metabolomic epigenetic maternal and/or offspring wellbeing\nenhancement breast milk micronutrient content, altered immunological factors, epigenetic metabolomic (subsample) maintenance healthy lactogenesis\nsecondary offspring outcomes phase are:\nneonatal adiposity pea pod\nbirthweight 2500–4000\xa0g, gestational age birth customised birthweight centile\nreduced adiposity gain infancy, infant feeding\nreduction cord blood c-peptide glycaemia gestation\npromotion offspring wellbeing healthy cardiometabolic factors, visceral adiposity  resistance, infancy\nalteration offspring metabolomic epigenetic perinatal samples, infant metabolic allergic wellbeing\nalteration gut microbiota microbiota infant metabolic allergic wellbeing\n\ndata biosample collection\nstudy trained staff using access-controlled, web-based database (medscinet, stockholm) managed staff mrc lifecourse epidemiology unit singapore institute sciences.']
S126-PMC5418719	PMC5418719	5/2017	S126-PMC5418719	['these results SUGGEST Vitamin D deficiency is RELATED to impaired Glucose tolerance and Insulin resistance.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 46)]	2	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('PR_000045358', 'insulin family protein', 88, 'insulin')]	0	['results  glucose tolerance  resistance.']
S10-PMC5539754	PMC5539754	8/2017	S10-PMC5539754	['our NOVEL FINDINGS IMPLY that seasonal variation in Insulin resistance MAY NOT be fully EXPLAINED by differences in Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 4), ('PROBABLE_UNDERSTANDING', 19), ('INCOMPLETE_EVIDENCE', 71), ('PROBABLE_UNDERSTANDING', 88)]	4	[('PR_000045358', 'insulin family protein', 52, 'insulin'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]	0	['seasonal  resistance  status.']
S16-PMC5539754	PMC5539754	8/2017	S16-PMC5539754	['the presence of Vitamin D receptors and Expression of 1-α-hydroxylase enzyme in Pancreatic Beta Cells SUGGEST that Vitamin D MAY BE a modulator of Insulin secretion and THUS, INFLUENCE Glucose Homeostasis [6].']	[('INCOMPLETE_EVIDENCE', 102), ('INCOMPLETE_EVIDENCE', 125), ('PROBABLE_UNDERSTANDING', 169), ('SUPERFICIAL_RELATIONSHIP', 175)]	4	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0010467', 'gene expression', 40, 'expression'), ('CL_0000169', 'type B pancreatic cell', 80, 'pancreatic beta cells'), ('UBERON_0001264', 'pancreas', 80, 'pancreatic'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('PR_000045358', 'insulin family protein', 147, 'insulin'), ('CHEBI_17234', 'glucose', 185, 'glucose'), ('GO_0042593', 'glucose homeostasis', 185, 'glucose homeostasis')]	0	['presence  receptors expression 1-α-hydroxylase enzyme pancreatic beta cells  modulator  secretion thus, glucose homeostasis [6].']
S17-PMC5539754	PMC5539754	8/2017	S17-PMC5539754	['in Pregnancy, the ASSOCIATION between low Vitamin D levels and abnormalities in Glucose tolerance is the subject of scientific DEBATE, with SOME STUDIES reporting that maternal Insulin sensitivity, fasting Glucose and Gestational diabetes are not associated with 25ohd [7], WHILE others have FOUND inverse ASSOCIATIONS between 25ohd, fasting Glucose [8] and risk of Gestational diabetes [9].']	[('SUPERFICIAL_RELATIONSHIP', 18), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('INCOMPLETE_EVIDENCE', 140), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 274), ('INCOMPLETE_EVIDENCE', 292), ('SUPERFICIAL_RELATIONSHIP', 306)]	6	[('GO_0007565', 'female pregnancy', 3, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_17234', 'glucose', 80, 'glucose'), ('PR_000045358', 'insulin family protein', 177, 'insulin'), ('CHEBI_17234', 'glucose', 206, 'glucose'), ('GO_0007565', 'female pregnancy', 218, 'gestational'), ('CHEBI_17234', 'glucose', 342, 'glucose'), ('GO_0007565', 'female pregnancy', 366, 'gestational')]	0	['pregnancy,  levels abnormalities glucose tolerance subject scientific debate, maternal  sensitivity, fasting glucose gestational diabetes 25ohd [7], 25ohd, fasting glucose [8] gestational diabetes [9].']
S30-PMC5539754	PMC5539754	8/2017	S30-PMC5539754	['due to the seasonal nature of 25Ohd concentrations in many parts of the world [32], and the OBSERVED ASSOCIATIONS between Vitamin D and Insulin resistance, it WOULD seem PRUDENT to HYPOTHESISE that seasonal variation of Glucose Homeostasis MAY BE MEDIATED through 25Ohd.']	[('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 101), ('FUTURE_PREDICTION', 159), ('IMPORTANT_CONSIDERATION', 170), ('FUTURE_WORK', 181), ('INCOMPLETE_EVIDENCE', 240), ('SUPERFICIAL_RELATIONSHIP', 247)]	7	[('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 30, '25OHD'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('PR_000045358', 'insulin family protein', 136, 'insulin'), ('CHEBI_17234', 'glucose', 220, 'glucose'), ('GO_0042593', 'glucose homeostasis', 220, 'glucose homeostasis'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 264, '25OHD')]	0	['due seasonal nature 25ohd concentrations parts world [32],   resistance, seasonal glucose homeostasis 25ohd.']
S105-PMC5539754	PMC5539754	8/2017	S105-PMC5539754	['GIVEN that the ASSOCIATION between early Gestation through extended winter and Insulin resistance is INDEPENDENT of Serum 25Ohd <30\xa0nmol/l, our NOVEL FINDINGS IMPLY that seasonal variation in Insulin resistance MAY NOT be fully EXPLAINED by differences in Vitamin D status.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 15), ('SUPERFICIAL_RELATIONSHIP', 101), ('INCOMPLETE_EVIDENCE', 144), ('PROBABLE_UNDERSTANDING', 159), ('INCOMPLETE_EVIDENCE', 211), ('PROBABLE_UNDERSTANDING', 228)]	7	[('GO_0007565', 'female pregnancy', 41, 'gestation'), ('PR_000045358', 'insulin family protein', 79, 'insulin'), ('UBERON_0001977', 'blood serum', 116, 'serum'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 122, '25OHD'), ('PR_000045358', 'insulin family protein', 192, 'insulin'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D')]	0	['given gestation winter  resistance serum 25ohd <30\xa0nmol/l, seasonal  resistance  status.']
S159-PMC5539754	PMC5539754	8/2017	S159-PMC5539754	['OUR FINDINGS SUGGEST that women at risk of Vitamin D deficiency in early Pregnancy have altered Glucose Metabolism in later Gestation, BUT the evidence is NOT CONSISTENT for Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 155)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_17234', 'glucose', 96, 'glucose'), ('GO_0006006', 'glucose metabolic process', 96, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'gestation'), ('PR_000045358', 'insulin family protein', 174, 'insulin')]	0	['women  pregnancy altered glucose metabolism gestation,  resistance.']
S13-PMC5758521	PMC5758521	1/2018	S13-PMC5758521	['SURPRISINGLY, high-dose Vitamin E (Α-Tocopherol) supplementation HAS BEEN ASSOCIATED with increased risk of low Birth weight8– a condition LINKED to Insulin-Like Growth Factor I (Igf-I) insufficiency9.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 65), ('SUPERFICIAL_RELATIONSHIP', 74), ('SUPERFICIAL_RELATIONSHIP', 139)]	4	[('CHEBI_27300', 'vitamin D', 24, 'vitamin E'), ('CHEBI_27725', 'butin', 35, 'α-tocopherol'), ('GO_0007567', 'parturition', 112, 'birth'), ('PR_000045358', 'insulin family protein', 149, 'insulin'), ('PR_000009659', 'laminin subunit gamma-2', 157, 'like growth factor I'), ('PR_000008919', 'interferon alpha-6', 179, 'IGF-I')]	0	['surprisingly, high-dose  (α-tocopherol) supplementation birth weight8– condition (igf-i) insufficiency9.']
S15-PMC5758521	PMC5758521	1/2018	S15-PMC5758521	['circulating Vitamin A and E concentrations HAVE BEEN inversely CORRELATED to adiposity and Insulin sensitivity in children11.']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 63)]	2	[('CHEBI_27300', 'vitamin D', 12, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 20, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 26, 'E'), ('PR_000045358', 'insulin family protein', 91, 'insulin')]	0	['circulating  e concentrations adiposity  sensitivity children11.']
S427-PMC5941617	PMC5941617	5/2018	S427-PMC5941617	['the imdiab xi study in which new onset t1dm children were given in the Vitamin D group Calcitriol at 0.25\xa0μg/2\xa0days or Nicotinamide at 25\xa0mg/kg/day REPORTED a reduction of Insulin requirements in the Vitamin D group [384].']	[('INCOMPLETE_EVIDENCE', 148)]	1	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 87, 'calcitriol'), ('CHEBI_17154', 'nicotinamide', 119, 'nicotinamide'), ('PR_000045358', 'insulin family protein', 172, 'insulin'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]	0	['imdiab xi onset t1dm children  calcitriol 0.25\xa0μg/2\xa0days nicotinamide 25\xa0mg/kg/day reduction   [384].']
S484-PMC5941617	PMC5941617	5/2018	S484-PMC5941617	['Animal models and in vitro studies report that Vitamin D MAY INFLUENCE both Pancreatic Insulin secretion and Insulin sensitivity in Skeletal muscle [446,447].']	[('INCOMPLETE_EVIDENCE', 57), ('SUPERFICIAL_RELATIONSHIP', 61)]	2	[('NCBITaxon_33208', 'Metazoa', 0, 'Animal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('UBERON_0001264', 'pancreas', 76, 'pancreatic'), ('PR_000045358', 'insulin family protein', 87, 'insulin'), ('PR_000045358', 'insulin family protein', 109, 'insulin'), ('UBERON_0004288', 'skeleton', 132, 'skeletal')]	0	['animal  pancreatic  secretion  sensitivity skeletal muscle [446,447].']
S491-PMC5941617	PMC5941617	5/2018	S491-PMC5941617	['REPORTED no correlation between Insulin sensitivity and Vitamin D levels, EVEN after weight loss [442].']	[('INCOMPLETE_EVIDENCE', 0), ('ANOMALY_CURIOUS_FINDING', 74)]	2	[('PR_000045358', 'insulin family protein', 32, 'insulin'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D')]	0	['reported  sensitivity  levels, loss [442].']
S497-PMC5941617	PMC5941617	5/2018	S497-PMC5941617	['other papers DESCRIBE a significant reduction of Insulin resistance index after Vitamin D supplementation [454,455].']	[('INCOMPLETE_EVIDENCE', 13)]	1	[('PR_000045358', 'insulin family protein', 49, 'insulin'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]	0	['reduction  resistance  supplementation [454,455].']
S499-PMC5941617	PMC5941617	5/2018	S499-PMC5941617	['more RECENT FINDINGS have reported no influence of DIFFERENT Vitamin D supplementation schedules on Serum Lipid levels, Glucose Homeostasis, glycated hemoglobin and Pancreatic Insulin secretion [457–459].']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 51)]	2	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('UBERON_0001977', 'blood serum', 100, 'serum'), ('CHEBI_18059', 'lipid', 106, 'lipid'), ('CHEBI_17234', 'glucose', 120, 'glucose'), ('GO_0042593', 'glucose homeostasis', 120, 'glucose homeostasis'), ('UBERON_0001264', 'pancreas', 165, 'pancreatic'), ('PR_000045358', 'insulin family protein', 176, 'insulin')]	0	[' supplementation schedules serum lipid levels, glucose homeostasis, glycated hemoglobin pancreatic  secretion [457–459].']
S500-PMC5941617	PMC5941617	5/2018	S500-PMC5941617	['a RECENT italian rct SHOWED that supplementation with Vitamin D (800\xa0iu/day) plus Docosahexanoic Acid IMPROVED Insulin-resistance, Lipid profile, aminotransferases levels, and activity score in obese children with non alcoholic fatty Liver disease and Vitamin D deficiency [460].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 102)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_36006', 'icosapentaenoic acid', 82, 'docosahexanoic acid'), ('PR_000045358', 'insulin family protein', 111, 'insulin'), ('CHEBI_18059', 'lipid', 131, 'lipid'), ('UBERON_0002107', 'liver', 234, 'liver'), ('CHEBI_27300', 'vitamin D', 252, 'vitamin D')]	0	['italian supplementation  (800\xa0iu/day) plus docosahexanoic acid -resistance, lipid profile, aminotransferases levels, activity score obese children alcoholic fatty liver disease  [460].']
S501-PMC5941617	PMC5941617	5/2018	S501-PMC5941617	['finally, two RECENT meta-analyses SHOWED that Vitamin D supplementation had no significant effect on Glucose and Insulin Metabolism [461] and on changes in the concentrations of inflammatory BIOMARKERS (C-Reactive Protein, tumor necrosis factor alpha, Il-6) in obese and overweight adolescents and Adults [462].']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 191)]	3	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('GO_0007369', 'gastrulation', 101, 'glucose ...'), ('GO_1901142', 'insulin metabolic process', 113, 'insulin metabolism'), ('PR_000045358', 'insulin family protein', 113, 'insulin'), ('PR_000005890', 'crooked neck-like protein 1', 203, 'C-reactive protein'), ('PR_000001470', 'interleukin-28B', 252, 'IL-6'), ('UBERON_0007023', 'adult organism', 298, 'adults')]	0	['finally, meta-analyses  supplementation glucose  metabolism [461] changes concentrations inflammatory (c-reactive protein, tumor necrosis alpha, il-6) obese overweight adolescents adults [462].']
S102-PMC6011374	PMC6011374	6/2018	S102-PMC6011374	['this is also CONSISTENT with another study that observed an increased risk of gdm with Vitamin D deficiency in early Pregnancy (aor: 3.40; 95% ci: 2.03–4.98 [17]) and offers POTENTIAL physiological CONNECTIONS between Vitamin D status and the progression of Insulin resistance in Pregnant women.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 174), ('SUPERFICIAL_RELATIONSHIP', 198)]	3	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D'), ('PR_000045358', 'insulin family protein', 258, 'insulin'), ('GO_0007565', 'female pregnancy', 280, 'pregnant')]	0	['gdm  pregnancy (aor: 3.40; 95% ci: 2.03–4.98 [17]) offers physiological  status progression  resistance pregnant women.']
